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Abstract: 
 
In recent years, cannabinoid type 2 receptors (CB2R) have emerged as promising therapeutic 
targets in a wide variety of diseases. Selective ligands of CB2R are devoid of the psychoactive 
effects typically observed for CB1R ligands. Based on our recent studies on a class of 
pyridazinone 4‐carboxamides, further structural modifications of the pyridazinone core were 
made to better investigate the structure–activity relationships for this promising scaffold with the 
aim to develop potent CB2R ligands. In binding assays, two of the new synthesized compounds 
[6‐(3,4‐dichlorophenyl)‐2‐(4‐fluorobenzyl)‐cis‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2,3‐
dihydropyridazine‐4‐carboxamide (2) and 6‐(4‐chloro‐3‐methylphenyl)‐cis‐N‐(4‐
methylcyclohexyl)‐3‐oxo‐2‐pentyl‐2,3‐dihydropyridazine‐4‐carboxamide (22)] showed high 
CB2R affinity, with Ki values of 2.1 and 1.6 nm, respectively. In addition, functional assays of 
these compounds and other new active related derivatives revealed their pharmacological 
profiles as CB2R inverse agonists. Compound 22 displayed the highest CB2R selectivity and 
potency, presenting a favorable in silico pharmacokinetic profile. Furthermore, a molecular 
modeling study revealed how 22 produces inverse agonism through blocking the movement of 
the toggle‐switch residue, W6.48. 
 
Keywords: ADMET calculations | cannabinoid receptors | CB2 inverse agonism | docking 
studies | synthesis 
 
Article: 
 
Introduction 
 
The cannabinoid subtype 2 receptor (CB2R) belongs to the rhodopsin‐like G‐protein‐coupled 
receptor (GPCR) superfamily and constitutes, along with the cannabinoid subtype 1 receptor  
(CB1R), the family of cannabinoid receptors (CBRs).1, 2 CBRs are mainly activated by three 
types of ligands: endogenous cannabinoids, such as N‐arachidonoylethanolamine and 2‐
arachidonoyl glycerol, phytocannabinoids, such as (−)‐trans‐Δ9‐tetrahydrocannabinol, and 
synthetic cannabinoids.3 In recent years, significant progress have been made toward understand 
the role played by CBRs in many physiological and pathophysiological conditions. 
 
CB1Rs and CB2Rs show certain common features and they share similar signaling mechanisms; 
nevertheless they differ in anatomic distribution. The former are expressed in several cell types 
and tissues, including muscle and liver cells, as well as spleen, pituitary gland, reproductive 
organs and adipose tissues.4 Nevertheless, they are predominantly distributed throughout the 
central nervous system (CNS) in which they are implicated in the control of many 
neurobiological processes, including nociception, control of movement, emesis, emotional 
response, motivated behavior, cognitive function and homeostasis.5, 6 CB2Rs are mostly 
expressed in immune cells such as monocytes, macrophages, and natural killer cells, in which 
they play an important role in mediating the immune‐modulatory function.7, 8 However, it has 
been reported that CB2Rs are also localized in other types of cells and tissues such as vascular 
endothelial cells, cardiomyocytes, bone cells, and tissues of the gastrointestinal tract.4 Moreover, 
CB2Rs have been found in activated microglia or astroglia, and might be also expressed by 
central neurons, especially under pathological conditions.9, 10 
 
CBRs have been proposed as potential therapeutic targets for the treatment of several 
diseases4, 11 and some nonselective CB1R/CB2R agonists are already approved drugs for use in 
use in the clinic (i.e., Sativex, Cesamet, Marinol). However, psychotropic side effects are the 
major limitation related to the therapeutic use of nonselective cannabinoid derivatives. It is well 
known that the undesirable effects of cannabinoids on the CNS are mediated by CB1R,12 and 
consequently the new goal for medicinal chemists has become the discovery of CB2R‐selective 
ligands. These ligands are devoid of the central side effects due to their limited distribution in the 
CNS, although there are a number of potential drawbacks for the immune system (e.g., 
immunosuppression). Furthermore, there is an increasing amount of evidence for the therapeutic 
potential of pharmacologically modulating the CB2R. Preclinical evidence supports that CB2R‐
selective ligands could be used for the treatment of various CNS‐related neurodegenerative 
disorders including Alzheimer's, Huntington's and Parkinson's diseases, multiple sclerosis and 
amyotrophic lateral sclerosis.10, 13-15 In addition to being a promising target for the treatment of 
pain and inflammation,15-17 the CB2R is also indicated for the treatment of irritable bowel 
syndrome, myocardial infarction, bone disorders, and different types of 
cancer.4, 15, 18, 19 However, none of the CB2 ligands tested in clinical trials have reached the 
market, probably due to their lack of efficacy.20 
 
Recently, we synthesized a new series of pyridazinone‐based derivatives21 endowed with CB2R 
affinity in the nanomolar range and good CB2R selectivity. Among these novel compounds, the 
6‐(4‐chloro‐3‐methylphenyl)‐2‐(4‐fluorobenzyl)‐N‐(4‐cis‐methylcyclo‐hexyl)‐3‐oxo‐2,3‐
dihydropyridazine‐4‐carboxamide (1, Figure 1) showed high CB2R affinity (KiCB2R=2.0±0.8 
nm) and notable selectivity (KiCB1R/KiCB2R >2000). To further explore structure–activity 
relationships in this new class of CB2R ligands, we modulated the design of compound 1, 
designated as a lead compound, to obtain derivatives 2–24 (Figure 1). Accordingly, we planned 
structural modifications at three positions (Ar, R1 and R2) of the dihydropyridazinone core, to 
evaluate the effect of their lipophilicity and steric hindrance on CBR affinity of this series of 
pyridazinone‐based derivatives. In this study, we report the synthesis, the preliminary 
pharmacological data and docking studies on the new pyridazinones 2–24 reported in Table 1. 
 
 
Figure 1. Structures of pyridazinone compounds 2–24. 
 
Table 1. Structures and binding data for compounds 2–24. 
 
Ki [nm][a] Selectivity[b] 
Compound Ar R1 R2 CB1R CB2R   
2 3,4‐dichlorophenyl 4‐fluorobenzyl 4‐cis‐methylcyclohexyl 213±18 2.1±0.2 101 
3 3,4‐dichlorophenyl 4‐fluorobenzyl 4‐trans‐methylcyclohexyl 85±7 90±7 0.94 
4 3,4‐dichlorophenyl 4‐fluorobenzyl cyclohexyl 350±31 6.3±0.5 55 
5 3,4‐dichlorophenyl 4‐fluorobenzyl cycloheptyl 226±25 7.2±0.9 31 
6 3,4‐dichlorophenyl 4‐fluorobenzyl adamantyl 1200±123 21±2 57 
7 3,4‐dichlorophenyl cyclohexylmethyl 4‐cis‐methylcyclohexyl 3300±315 4.2±0.3 786 
8 3,4‐dichlorophenyl cyclohexylmethyl 4‐trans‐methylcyclohexyl >10 000 10±1 >1000 
9 3,4‐dichlorophenyl cyclohexylmethyl cyclohexyl 6000±578 11±1 545 
10 3,4‐dichlorophenyl cyclohexylmethyl cycloheptyl >10 000 10±1 >1000 
11 3,4‐dichlorophenyl cyclohexylmethyl adamantyl 93±9 25±3 4 
12 3,4‐dichlorophenyl chloropentyl 4‐cis‐methylcyclohexyl >10 000 9.0±0.8 >1111 
13 3,4‐dichlorophenyl chloropentyl 4‐trans‐methylcyclohexyl 4000±395 16±2 250 
14 3,4‐dichlorophenyl chloropentyl cyclohexyl 5300±542 85±8 62 
15 3,4‐dichlorophenyl chloropentyl cycloheptyl 147±16 55±6 3 
16 3,4‐dichlorophenyl chloropentyl adamantyl >10 000 16±2 >625 
17 5‐bromothiophene 4‐fluorobenzyl 4‐cis‐methylcyclohexyl 1600±146 5.5±0.7 291 
18 5‐bromothiophene 4‐fluorobenzyl 4‐trans‐methylcyclohexyl 200±23 10.5±0.9 19 
19 5‐bromothiophene 4‐fluorobenzyl cyclohexyl 5600±559 8.4±0.9 667 
20 5‐bromothiophene 4‐fluorobenzyl cycloheptyl 800±78 110±13 7 
21 5‐bromothiophene 4‐fluorobenzyl adamantyl 6125±583 3.1±0.3 1976 
22 4‐chloro‐3‐methylphenyl pentyl 4‐cis‐methylcyclohexyl >10 000 1.6±0.2 >6250 
23 4‐chloro‐3‐methylphenyl pentyl cyclohexyl 2500±271 7.5±0.9 333 
24 4‐chloro‐3‐methylphenyl pentyl cycloheptyl 666±68 6.1±0.8 109 
 
Ki [nm][a] Selectivity[b] 
Compound Ar R1 R2 CB1R CB2R   
WIN 55,212‐2 – – – 13±2 2.5±0.3 5.2 
[a] Ki values for CB2Rs and CB1Rs were determined by competitive displacement of the radioligand [3H]CP 55,940. 
The Ki was calculated from the IC50 values determined from the binding curves, using the Cheng–Prusoff 
equation.22 Values are the mean±SEM of at least three independent experiments performed in triplicate. [b] 
(Ki CB1R)/(Ki CB2R). 
 
 
Scheme 1. Reagents and conditions: a) Br2, AcOH (for 25 and 27) or CH2Cl2 (for 26), RT, 8 h; 
b) diethyl malonate, NaH, THF, 0 °C–RT, 20–24 h; c) NH2NH2⋅H2O, EtOH, reflux, 24 h; d) Br2, 
AcOH, RT, 6 h; e) K2CO3, DMF, R1X, ultrasonic irradiation, RT, 2 h; f) 2 m NaOH, EtOH, 
reflux, 8 h; g) HOBt, EDC, R2NH2, CH2Cl2, 0 °C–RT, 12–24 h (for 2–16, 22–24); h) SOCl2, 
toluene, reflux, 3 h, then Et3N, R2NH2, CH2Cl2, 0 °C–RT, 12 h (for 17–21). 
 
EDC–HOBt mediated coupling reaction between acids 45–47, 49 and the appropriate amines 
afforded the desired carboxamide derivatives 2–16 and 22–24. Due to lower reaction yields for 
the coupling of acid 48 in these conditions, it was previously activated with thionyl chloride, 
then, treated with the appropriate amines to furnish the desired derivatives 17–21. 
 
Results and Discussion 
 
Chemistry 
 
Target 3‐oxo‐6‐aryl‐2,3‐dihydropyridazines 2–24 were synthesized as outlined in Scheme 1. α‐
Halogenation of commercial ketones 25–27 with bromine gave acyl halides 28–30. Nucleophilic 
substitution on the acyl halides with the enolate of diethyl malonate in anhydrous THF furnished 
diesters 31–33, which were converted into cyclic derivatives 34–36 by reaction with hydrazine 
hydrate in ethanol at reflux. Bromine‐assisted oxidation of dihydropyridazinones 34 and 36 in 
acetic acid provided pyridazinones 37 and 39. Ring oxidation and bromination of the thiophene 
moiety at the C5 position of 35 was accomplished by reaction with bromine in acetic acid to 
afford pyridazinone 38. N‐Alkylation of 37–39 in anhydrous DMF with the appropriate alkyl 
halide or benzyl halide in the presence of K2CO3, under ultrasound irradiation, afforded 
compounds 40–44, which were hydrolyzed with NaOH in ethanol to the corresponding 
carboxylic acids 45–49 in almost quantitative yield. 
 
Biological evaluation 
 
The CB1R and CB2R binding affinities of the novel 3‐oxo‐2,3‐dihydropyridazine‐4‐
carboxamides 2–24 were evaluated by radioligand binding assays performed by using transfected 
human CB1R (hCB1R) and CB2R (hCB2R) Chinese hamster ovary (CHO) cells. [3H]CP 55,940 
was used as the radiolabeled ligand. The experimental data (IC50 values) were converted 
into Ki values.22 The receptor affinities are shown in Table 1. For comparison, the Ki value of the 
mixed CB1R/CB2R ligand WIN 55,212‐2 is reported. 
 
The substitution of 3‐CH3 group on the benzene ring of the lead compound 1 with a second 
chlorine atom gave derivative 2, which retained good CB2R affinity (Ki=2.1±0.2 nm) with 
moderate selectivity (KiCB1R/KiCB2R=101), whereas its trans isomer 3 showed similar affinity 
for CB2R and CB1R (Ki=90±7 and 85±7 nm, respectively). The elimination of the methyl group 
from the cyclohexyl ring (compound 4) and homologation of the aliphatic ring to cycloheptyl (5) 
restored CB2R affinity (Ki=6.3±0.5 and Ki=7.2±0.9 nm, respectively) and moderate selectivity 
(KiCB1R/KiCB2R=55 and 31, respectively). Finally, the introduction of a bulky group in the 
carboxylic portion, such as 1‐adamantylamine, gave compound 6 which showed a 10‐fold 
decrease in CB2R affinity (Ki=21±2 nm) with respect to derivative 2. 
 
The same trend was observed in the small series of derivatives bearing a methylenecyclohexyl 
chain on the N2 atom of the pyridazinone ring, derivatives 7–11. All compounds showed a good 
CB2R affinity (Ki=4.2–25 nm), resulting the N‐(4‐cis‐methylcyclohexyl)‐carboxamide 7 having 
the best CB2R binding profile within this series (Ki=4.2±0.3 nm), similar to that of lead 
compound 1 and analogue 2. 
 
Next, we wanted to evaluate the effect of inserting a chloropentyl substituent at the N2 position 
of pyridazinone, thus we synthesized compounds 12–16. Derivatives of this series maintained 
good CB2R affinity (Ki, 9–85 nm), and carboxamide 12 showed high CB2R selectivity 
(KiCB1R/KiCB2R>1111) even though its KiCB2R affinity was 4.5‐fold less than lead 
compound 1. 
 
Therefore, the double chlorine atom substitution on the aromatic ring at C6, and either keeping 
the N2‐4‐fluorobenzyl group (compound 2) or introducing an N2‐methylcyclohexyl group (7) 
gave derivatives with similar KiCB2R values to the lead compound 1, whereas substitution with 
cyclopentyl at N2 gave 9 with a lower KiCB2R affinity. 
 
Having evaluated the effects of the substituent in the N2 position of the pyridazinone, we wanted 
to investigate replacement of the disubstituted phenyl group at C6 of the pyridazinone ring with a 
thiophene, thus we synthesized compounds 17–21. Within this series, both the derivative 17, 
bioisostere of the lead 1, and the N‐(adamantan‐1‐yl)‐carboxamide 21 showed interesting CB2R 
affinities (Ki=5.5 and 3.1 nm, respectively), and the latter compound was endowed with good 
selectivity (KiCB1R/KiCB2R >1976). 
 
Finally, we synthesized derivatives 22–24, three analogues of lead compound 1 bearing a pentyl 
chain at the N2 position, to confirm that the N‐4‐cis‐methylcyclohexyl group was the preferred 
substituent in the carboxamide moiety, as indicated from data obtained for 
compound 22 (KiCB2R=1.6±0.17 nm), which displayed the highest CB2R selectivity 
(KiCB1R/KiCB2R>6250). 
 
CB1R/CB2R‐stimulated cAMP binding 
 
Selected compounds characterized by high affinity and selectivity toward the CB2R were studied 
in functional assays to assess their behavior as agonists, antagonists or inverse agonists at the 
CB2R. Therefore, their modulation of forskolin‐stimulated cAMP levels in human CB2R‐
expressing CHO cells was investigated and compared with the reference agonist compound 
WIN 55,212‐2. This ligand (0.1 μm) decreased forskolin‐stimulated cAMP levels by 78 %, and 
compounds 2, 7, and 22 antagonized this effect in the concentration range 0.01–1 μm, with 
the 22 and 2 being the most potent molecules according to binding data. However, 
compounds 12, 13, 17 and 21, despite having high affinities for the CB2R, did not display an 
antagonistic effect on adenylyl cyclase activity inhibition induced by WIN 55,212‐2 (Figure 2). 
 
In addition, all the ligands tested in the functional assay were also evaluated for their ability to 
increase forskolin‐stimulated cAMP production in the concentration range 1–100 nm. As shown 
in Figure 3, the molecules under examination induced an increase in forskolin‐stimulated cAMP 
levels, suggesting their role as inverse agonists at the CB2R. 
 
 
Figure 2. Inhibition of forskolin‐stimulated cAMP levels by WIN 55,212‐2 (100 nm) and 
antagonism by 22, 7, 2, 21, 17, 12, and 13 (10–1000 nm) in hCB2R‐CHO cells. The effect of 
forskolin (5 μm) was set to 100 %. Values are the mean±SEM of four independent experiments 
(N=4). *P<0.05, compared with WIN 55,212‐2; analysis was by ANOVA followed by Dunnett's 
test. 
 
 
Figure 3. Effect of 22, 7, 2, 21, 17, 12, and 13 (1–100 nm) expressed as % of increase of 
forskolin‐stimulated cAMP accumulation in hCB2R‐CHO cells. The effect of forskolin (5 μm) 
was set to 100 %. Values are the mean±SEM of four independent experiments (N=4). *P<0.05, 
compared with Forskolin (5 μm); analysis was by ANOVA followed by Dunnett's test. 
 
Molecular modeling 
 
A previous study identified the binding site for the CB2R antagonist SR144528, using our CB2R 
inactive‐state (R) homology model.23 This study suggested that the SR144528 amide functional 
group is important for interacting with CB2R. In addition, aromatic stacking interactions in the 
transmembrane helix (TMH) 5–6 aromatic cluster were revealed to be crucial to the SR144528–
CB2R complex. Further exploration of the 1,8‐naphthyridin‐2(1H)‐one‐3‐carboxamide scaffold 
in the CB2R R model, showed that antagonists from this series bind in the TMH2–3–6–7 region 
with the C6 naphthyridine substituent directly blocking the W6.48(258) toggle switch.24 
 
In the current study, Glide docking studies revealed that the novel pyridazinones reported here 
bind in a similar orientation as the 1,8‐naphthyridin‐2(1H)‐one‐3‐carboxamides. The most potent 
and selective CB2R inverse agonist, 22, was docked in a previously published CB2R R‐state 
model.23-26 This homology model was pre‐equilibrated in a stearoyl‐
docosahexaenoylphosphatidylcholine (SDPC) bilayer for 300 ns to allow it to adjust in a lipidic 
environment23 (see the Experimental Section). A complete conformational analysis of 22 was 
performed to identify the global minimum energy conformer as well as other minimum energy 
conformations that 22 can adopt. This global minimum energy conformer has an intramolecular 
hydrogen bond between the pyridazin‐3(2H)‐one carbonyl oxygen and the amide hydrogen atom. 
This global minimum energy conformer was used in the docking studies. As shown in Figure 
4 A, pyridazinone 22 occupies the CB2R TMH2–3–6–7 region. 
 
 
Figure 4. A) An extracellular view of 22 (lavender) docked in the TMH2–3–6–7 region of 
CB2R. Carbon atoms of residues with which 22 has direct interactions are shown in purple. B) A 
side view of 22 (lavender, atoms contoured at their van der Waals radii) docked at CB2R. It is 
clear that 22 is adjacent to the toggle‐switch residue, W6.48 (green), and blocks the W6.48 χ1 
g+→trans associated with activation. 
 
The energy‐minimized 22–CB2R complex (Figure 4 A) displays four main binding site 
interactions. The carbonyl oxygen atom of the pyridazinone core is engaged in a hydrogen bond 
with S7.39(285) [hydrogen bond (O−O) distance=2.90 Å and (O−H−O) angle=166°], and the 
carbonyl oxygen of the 4‐cis‐methylcyclohexyl amide substituent establishes a hydrogen bond 
with K3.28(109) [hydrogen bond (O−O) distance=2.90 Å and (O−H−O) angle=150°]. In 
addition, the central pyridazin‐3(2H)‐one ring forms a tilted‐T aromatic stack with F2.57(87) 
(ring centroid to ring centroid distance=5.60 Å, and the angle between the ring planes=63°). 
Moreover, M6.55(265) establishes a Met–aromatic interaction with the 4‐chloro‐3‐methylphenyl 
moiety [distances to the central ring centroid from M6.55 side‐chain atoms: carbon preceding 
sulfur atom, CG (3.92 Å); sulfur atom, SD (3.60 Å); and terminal methyl carbon, CE (3.89 Å), 
see Figure 4 A] The ligand–receptor interaction energies for residues within 5 Å of 22 were also 
assessed. The ligand conformational cost for 22 was 0.89 kcal mol−1, bringing the total 
interaction energy to −65.70 kcal mol−1 (see Table S1). The Glide score for this dock was −9.50. 
The conformational change of W6.48 (χ1 g+→trans) is associated with receptor activation in 
class A GPCRs such as CB2R. This change can modulate the Pro kink in TMH6 (P6.50), causing 
an opening at the IC end of the receptor to form for G‐protein interaction.24 W6.48 is therefore 
considered to be part of the “toggle switch” for activation. As illustrated in Figure 4 B, the 4‐
chloro‐3‐methylphenyl pyridazinone substituent of 22 points toward TMH5 and extends deep 
enough in the binding pocket to block the movement of W6.48(258) and therefore keep its χ1 at 
g+. This is consistent with 22 acting as an inverse agonist at the CB2R. Therefore, this docking 
study provides a rational structural explanation for the ability of ligands such as 22 to prevent G‐
protein‐dependent CB2R activation. 
 
In silico ADMET parameters 
 
In silico prediction of properties related to absorption, distribution, metabolism, excretion and 
toxicity (ADMET) can help to efficiently prioritize the most promising molecules to be further 
developed from the early stages of the drug discovery process. The high predictive potential and 
the decreased time and cost associated with these in silico approaches have increased its use in 
the search for novel drug candidates.27-29 
 
The pharmacokinetic properties of the newly synthesized pyridazinones and of well‐known 
CB2R ligands such as SR144528 and HU308 were calculated in silico using QikProp in Maestro 
(Schrödinger package). This program calculates a set of 34 physicochemical descriptors based on 
the global minimum energy conformer of each molecule. 
 
According to our drug‐likeness prediction studies, the pyridazinones described herein follow the 
Lipinski and Jorgensen pharmacokinetics rules (Table 2).30, 31 As shown in Table 2, the 
prediction of blood–brain barrier permeability, human oral absorption, bioavailability, human 
intestinal permeability or binding to human serum albumin suggest that pyridazinones 2–24 have 
a suitable drug profile. The compounds presented here have solubility values that fall outside the 
range predicted by QikProp for 95 % of known oral drugs. Solubility issues are widely known in 
cannabinoid pharmacology because of their lipophilic nature.32, 33 Within all the structural 
subsets of pyridazinones, the derivatives bearing an adamantyl group at the R1 position 
(6, 11, 16, 21) display higher in silico lipophilicity values. 6‐(4‐Chloro‐3‐methylphenyl)‐3‐oxo‐
2‐pentyl‐2,3‐dihydropyridazine‐4‐carboxamides (22–24) display the best solubility among this 
series of compounds, being better than the widely used CB2R reference ligands SR144528 and 
HU308. 
 
Table 2. Physicochemical descriptors of compounds 2–24, SR144528 and HU308 calculated by 
QikProp integrated in Maestro. 
Compound QPlogP[a] QlogBB[b] QPPMDCK[c] QPlogKhsa[d] QPPCaco[e] Absorption [%][f] 
2 7.52 −0.01 10 000 1.64 2524 100 
3 7.56 −0.07 10 000 1.69 2248 100 
4 7.21 −0.10 10 000 1.53 2111 100 
5 7.45 −0.04 10 000 1.62 2328 100 
6 7.96 −0.13 9996 1.87 2053 100 
7 7.50 −0.22 5819 1.81 2149 100 
8 7.49 −0.22 5819 1.80 2165 100 
9 7.12 −0.04 8058 1.60 2905 100 
Compound QPlogP[a] QlogBB[b] QPPMDCK[c] QPlogKhsa[d] QPPCaco[e] Absorption [%][f] 
10 7.33 −0.03 7953 1.69 2869 100 
11 7.86 −0.14 6590 1.96 2412 100 
12 7.15 −0.11 10 000 1.50 1966 100 
13 7.26 −0.24 10 000 1.52 1840 100 
14 7.40 −0.23 10 000 1.57 1964 100 
15 7.70 −0.21 10 000 1.69 2054 100 
16 8.12 −0.13 10 000 1.87 2445 100 
17 7.09 0.05 10 000 1.52 2629 100 
18 7.12 0.11 10 000 1.52 2893 100 
19 6.76 0.10 10 000 1.36 2802 100 
20 7.02 0.01 9935 1.50 2375 100 
21 7.54 0.05 10 000 1.72 2631 100 
22 6.69 −0.37 2874 1.30 2494 100 
23 6.65 −0.56 2219 1.48 1963 100 
24 6.88 −0.52 2357 1.57 2076 100 
HU308 7.01 −0.52 2057 1.62 3738 100 
SR144528 7.61 0.11 5587 1.91 4606 100 
[a] Predicted octanol–water partition coefficient (−2.0–6.5). [b] Predicted log of the brain–blood partition coefficient 
(−3.0–1.2). [c] Predicted apparent Madin–Darby canine kidney (MDCK) cell permeability [nm s−1, <25 poor, >500 
good]. [d] Prediction of binding to human serum albumin (−1.5–1.5). [e] Apparent Caco‐2 cell permeability [nm s−1, 
intestinal drug permeability, <25 poor, >500 excellent]. QikProp predictions are for nonactive transport. [f] Human 
oral absorption in the GI [<25 % is poor]; [range of 95 % of drugs]. 
 
To further explore in silico metabolism and toxicity for these novel compounds, we calculated 
the parameters summarized in Tables S2 and S3 by using the admetSAR server.34 Over 70 % of 
human drug metabolism occurs via cytochrome P450 oxidases (CYP450).35 The most abundant 
CYP450 isoenzymes in human liver and intestine are CYP3A4, CYP2C9 and CYP2D6.36 The 
pharmacokinetic behavior of drugs can be determined by their interactions with these enzymes, 
because their inhibition can affect drug clearance, consequently enhancing toxicity. Therefore, it 
is important to predict whether a new compound is a substrate, an inhibitor or an inducer of these 
CYP isoforms in early drug discovery phases. As shown in Table S2, compounds 22–24 present 
the best metabolic profiles in that they are substrates but not inhibitors of the most abundant 
isoform CYP3A4. These compounds will not hamper the biotransformation of drugs metabolized 
by this cytochrome P450 enzyme, whereas certain inhibitors could trigger adverse side effects. 
This difference in the metabolism among pyridazinones might be due to the presence of halogens 
in the molecule (derivatives 22–24 have only one halogen, whereas the other derivatives have at 
least two halogens per structure).37, 38 
 
In terms of toxicity, as shown in Table S3, the safety profile of all ligands reported here are 
favorable, because they present low cardiotoxicity and are nonmutagenic and noncarcinogenic. 
Low oral toxicity values were found also for the reference compounds SR144528 and HU308. In 
addition, the predicted median lethal dose (LD50 in rat model) for these compounds is in the 
range of most FDA‐approved small‐molecule drugs.39, 40 Therefore, taking the pharmacological 
and ADMET prediction data into consideration, the highly selective CB2R inverse 
agonist 22 might serve as a lead structure for further optimizing this novel class of CB2R ligands 
in terms of potency and pharmacokinetic properties. 
 
Conclusions 
 
The modulation of the 6‐aryl‐3‐oxo‐2,3‐dihydropyridazine‐4‐carboxamide scaffold in three 
different positions, the N2 chain, C4 carboxamide moiety and C6‐aryl ring, led us to determine 
the key features of this novel class of CB2R ligands. In general, the N‐4‐cis‐methylcyclohexyl 
group was the preferred substituent in the C4 carboxamide moiety; the derivatives bearing this 
group had high CB2R affinity (KiCB2R ranging from 1.6 to 9.0 nm) and selectivity 
(KiCB1R/KiCB2R from 101 to >6250). Concerning the N2 position, all inserted chains showed a 
good CB2R binding profile, especially the 5‐chloropentyl and 4‐fluorobenzyl groups; however, 
the presence of a 3,4‐disubstituted aromatic system in the C6 position provides a better binding 
profile for CB2Rs. 
 
Docking studies on compound 22 provides a rational structural explanation for the ability of 
these novel derivatives to act as inverse agonists at CB2R, preventing G‐protein‐dependent CB2R 
activation. 
 
The in silico prediction of the pharmacokinetic properties suggest that novel pyridazinones have 
a suitable drug‐like profile. Compound 22, and its congeners, display the best solubility values 
from this series, and have improved solubility over the reference compounds SR144528 and 
HU308. Finally, calculations to predict toxicity and metabolism showed compound 22 acts as a 
substrate, but not an inhibitor, for the most abundant CYP450 isoenzymes, and presents the best 
metabolic profile in this novel class of pyridazinones. 
 
In summary, compound 22, a very potent and selective CB2R inverse agonist has been identified 
with favorable properties that indicate this compound could be a lead for drug development. 
 
Experimental Section 
 
Chemistry 
 
All reactions involving air‐ or moisture‐sensitive compounds were performed under a nitrogen 
atmosphere. Solvents and reagents were obtained from commercial suppliers and were used 
without further purification. The starting ketones 25–27 and amines for the synthesis of final 
compounds were purchased from Sigma–Aldrich. Ultrasonic irradiation experiments were 
carried out in a Bandelin Sonorex RK‐100 H ultrasonic bath. Flash column chromatography was 
performed either on an automated FlashMaster system (Biotage) with pre‐packed Biotage SNAP 
silica gel cartridges or manually on silica gel (Kieselgel 60, 0.040–0.063 mm, Merck). Thin layer 
chromatography (TLC) was performed with Polygram SIL N‐HR/HV254 pre‐coated plastic sheets 
(0.2 mm) or aluminum sheets (Kieselgel 60 F254, Merck). Melting points were obtained on a 
Köfler melting point apparatus and are uncorrected. IR spectra were recorded on nujol mulls on 
NaCl plates with a Jasco FTIR 460 Plus spectrophotometer and are expressed in ν [cm−1]. NMR 
experiments were performed on a Bruker Avance III Nanoboy 400 system (400.13 MHz for 1H,  
100.62 MHz for 13C). Spectra were acquired using deuterated chloroform (CDCl3) or deuterated 
dimethylsulfoxide ([D6]DMSO) as solvents. Chemical shifts (δ) for 1H and 13C NMR spectra are 
reported in parts per million (ppm) using the residual nondeuterated solvent resonance as the 
internal standard (CDCl3: 7.26 and 77.16 ppm, respectively; [D6]DMSO: 2.50 and 39.52 ppm, 
respectively). Data are reported as follows: chemical shift (listed in descending order), 
multiplicity (s, singlet; br s, broad singlet; d, doublet; dd, double doublet; t, triplet; q, quadruplet; 
m, multiplet), coupling constants (J) in Hertz (Hz), and integral. LC–MS analyses in positive‐ion 
mode were performed on an Agilent 1100 LC–MSD system consisting of a single quadrupole 
detector mass spectrometer equipped with an electrospray ionization (ESI) interface and a 
photodiode array detector, the range of which was 120–550 nm. LC analysis was performed at 
room temperature with MeCN/H2O (8:2) as the mobile phase at a flow rate of 0.9 mL min−1. All 
final compounds were of ≥95 % purity as determined by elemental analysis on a PerkinElmer 
240‐B analyzer for C, H, and N. 
 
Synthesis of acyl bromides 28–30 
 
General method A: Bromine (3.02 mL, 59.3 mmol, 1 equiv) was dropwise added to a stirred 
solution of the ketone (59.3 mmol, 1 equiv) in glacial AcOH (65 mL), and the resulting solution 
was stirred at room temperature for 8 h. Then, ice‐water was poured into reaction flask and the 
resulting precipitate was filtered, washed with H2O, and air‐dried. The resulting crude product 
was purified by column flash chromatography using appropriate eluents. 
 
General method B: A solution of bromine (4.0 mL, 79.2 mmol, 1 equiv) in CH2Cl2 (40 mL) was 
dropwise added to a stirred solution of the ketone (79.2 mmol, 1 equiv) in CH2Cl2 (48 mL). The 
resulting mixture was stirred at room temperature for 1 h, then neutralized with saturated 
NaHCO3 aqueous solution. The organic layer was separated in a separating funnel and washed 
with brine. The organic solution was dried (Na2SO4) and the solvent removed under reduced 
pressure. The resulting residue was purified by column flash chromatography using appropriate 
eluents. 
 
Bromo‐1‐(3,4‐dichlorophenyl)ethan‐1‐one (28): Reaction of ketone 25 according to method A 
afforded a yellow solid, which was purified by flash chromatography (petroleum ether/EtOAc 
95:5) to give 28 as a white solid (14.9 g, 94 %). Rf=0.45 (petroleum ether/EtOAc 95:5); m.p.: 
44–45 °C; 1H NMR (400 MHz, CDCl3): δ=8.07 (s, 1 H), 7.81 (d, J=8.3 Hz, 1 H), 7.58 (d, J=8.3 
Hz, 1 H), 4.38 ppm (s, 2 H). 
 
Bromo‐1‐(thiophen‐2‐yl)ethan‐1‐one (29): Reaction of ketone 26 according to method B 
afforded a dark oil, which was purified by flash chromatography (petroleum ether/EtOAc 95:5) 
to give 29 as a yellow oil (14.9 g, 92 %). Rf=0.33 (petroleum ether/EtOAc 95:5); 1H NMR (400 
MHz, CDCl3): δ=7.81 (t, J=2.9 Hz, 1 H), 7.72 (d, J=4.5 Hz, 1 H), 7.17 (d, J=2.4 Hz, 1 H), 4.36 
ppm (s, 2 H). 
 
See the Supporting Information for compound 30. 
 
General procedure for the preparation of ketodiester derivatives 31–33 
 
A solution of diethyl malonate (1.83 mL, 12 mmol, 1.2 equiv) in anhydrous THF (6.5 mL) was 
added to a suspension of NaH (60 % dispersion in mineral oil, 0.480 g, 20 mmol, 2 equiv) in 
anhydrous THF (26 mL) under N2 flow at 0 °C, and the mixture was stirred for 1 h. Then, a 
solution of bromoketone (10 mmol, 1 equiv) in anhydrous THF (4 mL) was added dropwise and 
the resulting mixture was stirred at room temperature until complete conversion of the starting 
materials (monitored by TLC). The reaction was quenched with saturated NH4Cl aqueous 
solution, and the aqueous layer extracted with EtOAc. The combined organic layers were washed 
with H2O and brine, then dried over Na2SO4. The solvent was removed under reduced pressure 
and the resulting residue was purified by column flash chromatography with appropriate eluents. 
 
Diethyl 2‐[2‐(3,4‐dichlorophenyl)‐2‐oxoethyl]malonate (31): A mixture of diethyl malonate, 
NaH and 28 was stirred at room temperature for 20 h. The crude product of the reaction was 
purified by flash chromatography (petroleum ether/EtOAc 9:1) to afford 31 as a yellow oil (2.7 
g, 77 %). Rf=0.30 (petroleum ether/EtOAc 9:1); 1H NMR (400 MHz, CDCl3): δ=8.05 (s, 1 H), 
7.79 (d, J=8.4 Hz, 1 H), 7.55 (d, J=8.4 Hz, 1 H), 4.11 (q, J=7.1 Hz, 4 H), 4.03 (t, J=6.9 Hz, 
1 H), 3.55 (d, J=7.0 Hz, 2 H), 1.28 ppm (t, J=7.1 Hz, 6 H). 
 
See the Supporting Information for compounds 32 and 33. 
 
General procedure for the preparation of dihydropyridazinone derivatives 34–36 
 
Hydrazine monohydrate (64–65 %, 0.79 mL, 16.5 mmol, 1.1 equiv) was added dropwise to an 
ice‐bath‐cooled solution of malonate derivatives 31–33 (15 mmol, 1 equiv) in absolute ethanol 
(75 mL). The resulting solution was warmed to room temperature, then heated at reflux for 24 h. 
The solution was allowed to stand at room temperature and the resulting precipitate was isolated 
by vacuum filtration, washed with cold water, and dried in air. The obtained solid was purified 
by column flash chromatography using appropriate eluents. 
 
Ethyl 5‐(3,4‐dichlorophenyl)‐2‐oxo‐1,2,3,4‐tetrahydropyridine‐3‐carboxylate (34): From 
reaction of 31 was obtained a solid, which was purified by flash chromatography (petroleum 
ether/EtOAc 6:4) to give 34 as a pale yellow solid (2.79 g, 59 %). Rf=0.51 (petroleum 
ether/EtOAc 6:4); m.p.: 166–168 °C; 1H NMR (400 MHz, CDCl3): δ=8.96 (s, 1 H; NH, 
exchanged with D2O), 7.84 (s, 1 H), 7.56 (d, J=8.5 Hz, 1 H), 7.48 (d, J=8.4 Hz, 1 H), 4.25 
(q, J=7.2 Hz, 2 H), 3.61 (t, J=7.5 Hz, 1 H), 3.39 (dd, J=17.0, 7.9 Hz, 1 H), 3.05 (dd, J=17.0, 6.9 
Hz, 1 H), 1.28 ppm (t, J=7.2 Hz, 3 H). 
 
See the Supporting Information for compounds 35 and 36. 
 
General procedure for the preparation of pyridazinone derivatives 37–39 
 
A solution of bromine (0.51 mL, 10 mmol, 2 equiv) in glacial AcOH (8 mL) was added dropwise 
over 30 min to a stirred solution of dihydropyridazinone 34–36 (5 mmol, 1 equiv) in glacial 
AcOH (30 mL). The resulting mixture was stirred at room temperature for 6–8 h. Then, the 
solution was poured into ice‐water, and the aqueous solution was extracted into EtOAc using a 
separating funnel. The collected organic phases were washed with H2O, saturated 
NaHCO3 solution and brine, then dried (Na2SO4) and concentrated under reduced pressure to 
yield a residue, which was purified by column flash chromatography using appropriate eluents. 
 
Ethyl 6‐(3,4‐dichlorophenyl)‐3‐oxo‐2,3‐dihydropyridazine‐4‐carboxylate (37): The general 
procedure for the preparation of pyridazinones was used to oxidize 34. The reaction mixture was 
stirred for 8 h and the obtained crude product purified by flash chromatography (petroleum 
ether/EtOAc 1:1) to afford 37 as a pale yellow solid (0.85 g, 54 %). Rf=0.47 (petroleum 
ether/EtOAc 1:1); m.p.: 188–190 °C; 1H NMR (400 MHz, CDCl3): δ=8.26 (s, 1 H), 7.94 (s, 1 H), 
7.66 (d, J=8.3 Hz, 1 H), 7.55 (d, J=8.3 Hz, 1 H), 4.47 (q, J=7.1 Hz, 2 H), 1.44 ppm (t, J=7.0 Hz, 
3 H); 13C NMR (101 MHz, CDCl3): δ=162.79 (C), 158.25 (C), 143.09 (C), 134.31 (C), 133.65 
(C), 133.63 (CH), 132.71 (CH), 131.08 (C), 130.75 (C), 127.76 (CH), 124.93 (CH), 62.60 (CH2), 
14.22 ppm (CH3). 
 
See the Supporting Information for compounds 38 and 39. 
 
General procedure for the preparation of N‐alkylpyridazinone derivatives 40–44 
 
K2CO3 (1.65 g, 12 mmol, 3 equiv) then the appropriate alkyl or benzyl halide (12 mmol, 3 equiv) 
were added to a solution of pyridazinone 37–39 (4 mmol, 1 equiv) in anhydrous DMF (18 mL). 
The resulting suspension was subjected to ultrasound irradiation for 2 h at room temperature. 
Then the reaction mixture was poured into ice‐water, filtered, and extracted with EtOAc in a 
separating funnel. The collected organic phases were washed with H2O, 5 % LiCl solution and 
brine, then dried (Na2SO4) and concentrated under reduced pressure. The resulting residue was 
purified by column flash chromatography using appropriate eluents. 
 
Ethyl 6‐(3,4‐dichlorophenyl)‐2‐(4‐fluorobenzyl)‐3‐oxo‐2,3‐dihydropyridazine‐4‐carboxylate 
(40): From the reaction between pyridazinone 37 and 4‐fluorobenzyl bromide was obtained a 
residue, which was purified by flash chromatography (petroleum ether/EtOAc 8:2) to 
obtain 40 as a pale yellow solid (1.3 g, 78 %). Rf=0.47 (petroleum ether/EtOAc 7:3); m.p.: 139–
140 °C; 1H NMR (400 MHz, CDCl3): δ=8.15 (s, 1 H), 7.90 (s, 1 H), 7.62 (d, J=8.3 Hz, 1 H), 
7.57–7.48 (m, 3 H), 7.02 (t, J=8.0 Hz, 2 H), 5.40 (s, 2 H), 4.43 (q, J=6.9 Hz, 2 H), 1.41 ppm 
(t, J=7.0 Hz, 3 H); 13C NMR (101 MHz, CDCl3): δ=163.93 (C), 163.30 (CF), 161.28 (CF), 
156.24 (C), 141.39 (C), 134.10 (C), 133.94 (C), 133.59 (C), 131.41 (CH), 131.18 (C), 131.13 
(CH), 131.04 (2×CH), 130.60 (C), 127.63 (CH), 124.84 (CH), 115.71 (CH), 115.50 (CH), 62.49 
(CH2), 55.82 (CH2), 14.21 ppm (CH3). 
 
See the Supporting Information for compounds 41–44. 
 
General procedure for the preparation of pyridazinone carboxylic acid derivatives 45–49 
 
NaOH (2 m, 50 mL) was added to a stirred solution of pyridazinone ethyl ester (3 mmol) in 
EtOH (50 mL). The resulting mixture was heated at reflux and stirred overnight. Then, the 
solution was allowed to cool to room temperature and acidified with HCl (6 m). The resulting 
precipitate was filtered under vacuum, washed with H2O and air‐dried to yield the analytically 
pure acid. 
 
6‐(3,4‐Dichlorophenyl)‐2‐(4‐fluorobenzyl)‐3‐oxo‐2,3‐dihydropyridazine‐4‐carboxylic acid 
(45): Alkaline saponification in hydroalcoholic NaOH of pyridazinone ethyl ester 40 furnished 
acid 45 as a pink solid (1.1 g, 92 %). Rf=0.46 (CHCl3/MeOH 9:1); m.p.: 200–201 °C; 1H NMR 
(400 MHz, CDCl3): δ=8.60 (s, 1 H), 7.97 (s, 1 H), 7.67 (d, J=8.5 Hz, 1 H), 7.60 (d, J=8.4 Hz, 
1 H), 7.54–7.48 (m, 2 H), 7.07 (t, J=8.1 Hz, 2 H), 5.49 ppm (s, 2 H); 13C NMR (101 MHz, 
CDCl3): δ=164.24 (CF), 162.72 (C), 161.78 (CF), 160.41 (C), 144.63 (C), 135.19 (C), 133.98 
(C), 132.99 (CH), 132.96 (C), 131.32 (CH), 131.21 (CH), 131.13 (CH), 129.93 (C), 127.99 
(CH), 126.72 (C), 125.14 (CH), 116.10 (CH), 115.88 (CH), 56.32 ppm (CH2). 
 
See the Supporting Information for compounds 46–49. 
 
Synthesis of carboxamide derivatives 2–24 
 
General procedure A: HOBt (0.20 g, 1.5 mmol, 1.5 equiv) and EDC (0.38 g, 2 mmol, 2 equiv) 
were added to a stirred solution of acids 45–47, or 49 (1 mmol, 1 equiv) in CH2Cl2 (10 mL). The 
resulting mixture was stirred at room temperature for 30 min. Next, a solution of the appropriate 
amine in CH2Cl2 (10 mL) was added dropwise at 0 °C. The reaction mixture was allowed to 
stand at room temperature, and then stirred for 12–24 h. The solution was then poured into a 
separating funnel and H2O was added. The aqueous phase was separated, and extracted with 
CH2Cl2. The combined organic phases were washed with H2O and brine, dried (Na2SO4) and 
concentrated under reduced pressure. The analytically pure product was isolated by flash column 
chromatography using appropriate eluents. 
 
General procedure B: A solution of acid 48 (410 mg, 1.0 mmol, 1 equiv) and thionyl chloride 
(0.22 mL, 3 mmol, 3 equiv) in toluene (9 mL) was heated at reflux for 3 h. Then, the excess 
thionyl chloride was removed under reduced pressure and the resulting dark solid was dissolved 
in CH2Cl2 (15 mL). The appropriate amine (1.5 equiv) and Et3N (1.5 equiv) in CH2Cl2 (15 mL) 
was added dropwise at 0 °C to the solution. The reaction mixture was allowed to stand at room 
temperature and stirred for 12 h. Then the mixture was poured into a separating funnel and H2O 
was added. The aqueous phase was separated and extracted with CH2Cl2. The combined organic 
phases were washed with H2O, dried (Na2SO4) and concentrated under reduced pressure. The 
analytically pure product was isolated by flash column chromatography using appropriate 
eluents. 
 
6‐(3,4‐Dichlorophenyl)‐2‐(4‐fluorobenzyl)‐cis‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2,3‐
dihydropyridazine‐4‐carboxamide (2) and 6‐(3,4‐dichlorophenyl)‐2‐(4‐fluorobenzyl)‐trans‐
N‐(‐4‐methylcyclohexyl)‐3‐oxo‐2,3‐dihydropyridazine‐4‐carboxamide (3): 4‐
Methylcyclohexylamine and 45 were reacted according to general procedure A to afford the title 
products. The reaction mixture was stirred for 18 h, then the cis/trans isomers were separated by 
flash chromatography (petroleum ether/EtOAc 9:1). 
 
Compound 2 (111 mg, 23 %), white solid. Rf=0.41 (petroleum ether/EtOAc 85:15); m.p.: 130–
132 °C; 1H NMR (400 MHz, CDCl3): δ=9.80 (d, J=7.9 Hz, 1 H; NH, exchanged with D2O), 8.63 
(s, 1 H), 7.98 (d, J=2.1 Hz, 1 H), 7.68 (dd, J=8.5, 2.2 Hz, 1 H), 7.55 (d, J=8.4 Hz, 1 H), 7.49 
(dd, J=8.5, 5.5 Hz, 2 H), 7.05 (t, J=8.6 Hz, 2 H), 5.45 (s, 2 H), 4.26–4.18 (m, 1 H), 1.86–1.77 (m, 
2 H), 1.71–1.56 (m, 5 H), 1.33–1.20 (m, 2 H), 0.98 ppm (d, J=6.5 Hz, 3 H); 13C NMR (101 MHz, 
CDCl3): δ=163.96 (CF), 161.50 (CF), 160.43 (C), 159.74 (C), 143.14 (C), 134.22 (C), 134.00 
(C), 133.59 (C), 131.09 (C), 131.03 (CH), 130.91 (CH), 130.87 (CH), 130.79 (CH), 130.39 (C) 
127.86 (CH), 125.06 (CH), 115.80 (CH), 115.59 (CH), 55.54 (CH2), 49.95 (CH), 30.98 (CH), 
30.06 (2×CH2), 29.45 (2×CH2), 21.49 ppm (CH3); IR:  =1681 (C=O), 3274 cm−1 (NH); MS 
(ESI): m/z: calcd for C25H24FCl2N3O2: 487.1; found: 488.1 [M+H]+; elemental analysis calcd (%) 
for C25H24FCl2N3O2: C 61.48, H 4.95, N 8.60; found: C 61.59, H 4.94, N 8.61. 
 
Compound 3 (58 mg, 12 %), white solid. Rf=0.50 (petroleum ether/EtOAc 85:15); m.p.: 136–
138 °C; 1H NMR (400 MHz, CDCl3): δ=9.40 (d, J=8.0 Hz, 1 H; NH, exchanged with D2O), 8.63 
(s, 1 H), 7.98 (s, 1 H), 7.68 (d, J=8.4 Hz, 1 H), 7.55 (d, J=8.4 Hz, 1 H), 7.47 (t, J=6.9 Hz, 2 H), 
7.04 (t, J=8.5 Hz, 2 H), 5.43 (s, 2 H), 3.97–3.75 (m, 1 H), 2.09–1.98 (m, 2 H), 1.83–1.71 (m, 
2 H), 1.64 (s, 1 H), 1.39–1.23 (m, 2 H), 1.17–1.03 (m, 2 H), 0.91 ppm (d, J=6.5 Hz, 3 H); 13C 
NMR (101 MHz, CDCl3): δ=162.93 (CF), 160.47 (CF), 159.39 (C), 158.61 (C), 142.18 (C), 
133.23 (C), 132.96 (C), 132.58 (C), 130.06 (C), 130.02 (CH), 129.96 (C), 129.74 (CH), 129.66 
(CH), 129.29 (CH), 126.86 (CH), 124.06 (CH), 114.82 (CH), 114.60 (CH), 54.79 (CH2), 48.10 
(CH), 32.76 (2×CH2), 31.76 (2×CH2), 30.90 (CH), 21.16 ppm (CH3); IR:  =1677 (C=O), 3280 
cm−1 (NH); MS (ESI): m/z: calcd for C25H24FCl2N3O2: 487.1; found: 488.1 [M+H]+; elemental 
analysis calcd (%) for C25H24FCl2N3O2: C 61.48, H 4.95, N 8.60; found: C 61.55, H 4.96, N 
8.59. 
 
See the Supporting Information for compounds 4–6. 
 
2‐(Cyclohexylmethyl)‐6‐(3,4‐dichlorophenyl)‐cis‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2,3‐
dihydropyridazine‐4‐carboxamide (7) and 2‐(cyclohexylmethyl)‐6‐(3,4‐dichlorophenyl)‐
trans‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2,3‐dihydropyridazine‐4‐carboxamide (8): 4‐
Methylcyclohexylamine and 46 were reacted according to general procedure A to afford the title 
products. The reaction mixture was stirred for 18 h, then the cis/trans isomers were separated by 
flash chromatography (petroleum ether/EtOAc 95:5). 
 
Compound 7 (90 mg, 19 %), white solid. Rf=0.38 (petroleum ether/EtOAc 9:1); m.p.: 131–
132 °C; 1H NMR (400 MHz, CDCl3): δ=9.88 (d, J=7.8 Hz, 1 H; NH, exchanged with D2O), 8.63 
(s, 1 H), 7.98 (s, 1 H), 7.69 (d, J=8.3 Hz, 1 H), 7.55 (d, J=8.3 Hz, 1 H), 4.25–4.21 (m, 1 H), 4.19 
(d, J=7.5 Hz, 2 H), 2.10–2.00 (m, 1 H), 1.89–1.57 (m, 11 H), 1.34–1.04 (m, 8 H), 0.97 ppm 
(d, J=6.4 Hz, 3 H); 13C NMR (101 MHz, CDCl3): δ=159.73 (C), 159.17 (C), 141.36 (C), 133.27 
(C), 132.95 (C), 132.51 (C), 129.96 (CH), 129.36 (CH), 128.70 (C), 126.79 (CH), 124.00 (CH), 
57.72 (CH2), 44.95 (CH), 35.91 (CH), 29.99 (CH), 29.52 (2×CH2), 29.09 (2×CH2), 28.44 
(2×CH2), 25.24 (CH2), 24.62 (2×CH2), 20.44 ppm (CH3); IR:  =1688 (C=O), 3273 cm−1 (NH); 
MS (ESI): m/z: calcd for C25H31Cl2N3O2: 475.2; found: 476.2 [M+H]+; elemental analysis calcd 
(%) for C25H31Cl2N3O2: C 63.02, H 6.56, N 8.82; found: C 62.88, H 6.55, N 8.80. 
 
Compound 8 (47 mg, 10 %), white solid. Rf=0.55 (petroleum ether/EtOAc 9:1); m.p.: 133–
135 °C; 1H NMR (400 MHz, CDCl3): δ=9.52 (d, J=8.0 Hz, 1 H; NH, exchanged with D2O), 8.63 
(s, 1 H), 7.98 (s, 1 H), 7.69 (d, J=8.5 Hz, 1 H), 7.55 (d, J=8.5 Hz, 1 H), 4.42 (d, J=7.3 Hz, 1 H), 
4.17 (d, J=7.4 Hz, 2 H), 3.93–3.83 (m, 1 H), 2.12–2.02 (m, 3 H), 1.82–1.55 (m, 9 H), 1.40–1.03 
(m, 7 H), 0.92 ppm (d, J=6.5 Hz, 3 H); 13C NMR (101 MHz, CDCl3): δ=160.12 (C), 142.49 (C), 
134.23 (C), 134.00 (C), 133.53 (C), 132.97 (C), 130.98 (CH), 130.54 (CH), 129.69 (C), 127.82 
(CH), 125.04 (CH), 58.99 (CH2), 49.06 (CH), 36.95 (CH), 33.80 (2×CH2), 32.81 (2×CH2), 31.94 
(CH), 30.59 (2×CH2), 26.23 (CH2), 25.62 (2×CH2), 22.18 ppm (CH3); IR:  =1690 (C=O), 3275 
cm−1 (NH); MS (ESI): m/z: calcd for C25H31Cl2N3O2: 475.2; found: 476.2 [M+H]+; elemental 
analysis calcd (%) for C25H31Cl2N3O2: C 63.02, H 6.56, N 8.82; found: C 63.10, H 6.58, N 8.83. 
 
See the Supporting Information for compounds 9–11. 
 
2‐(5‐Chloropentyl)‐6‐(3,4‐dichlorophenyl)‐cis‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2,3‐
dihydropyridazine‐4‐carboxamide (12) and 2‐(5‐chloropentyl)‐6‐(3,4‐dichlorophenyl)‐
trans‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2,3‐dihydropyridazine‐4‐carboxamide (13): General 
procedure A for the synthesis of carboxamides was used to convert acid 47 and 4‐
methylcyclohexylamine into the title products. The reaction mixture was stirred for 18 h, then 
the cis/trans isomers were separated by flash chromatography (petroleum ether/EtOAc 87:13). 
 
Compound 12 (82 mg, 17 %), colorless oil. Rf=0.42 (petroleum ether/EtOAc 85:15); 1H NMR 
(400 MHz, CDCl3): δ=9.90 (d, J=7.8 Hz, 1 H; NH, exchanged with D2O), 8.64 (s, 1 H), 7.99 (s, 
1 H), 7.69 (dd, J=8.4, 2.2 Hz, 1 H), 7.55 (d, J=8.4 Hz, 1 H), 4.34 (t, J=7.4 Hz, 2 H), 4.28–4.21 
(m, 1 H), 3.47 (t, J=7.0 Hz, 2 H), 1.99–1.79 (m, 4 H), 1.72–1.59 (m, 9 H), 1.56–1.44 (m, 2 H), 
0.97 ppm (d, J=6.5 Hz, 3 H); 13C NMR (101 MHz, CDCl3): δ=159.64 (C), 158.90 (C), 141.75 
(C), 133.20 (C), 133.00 (C), 132.53 (C), 129.97 (CH), 129.51 (CH), 128.79 (C), 126.81 (CH), 
124.00 (CH), 69.25 (CH2) 51.94 (CH2), 44.80 (CH), 30.12 (CH), 29.06 (2×CH2), 28.53 (2×CH2), 
28.39 (CH2), 27.31 (CH2), 22.41 (CH2), 20.56 ppm (CH3); IR:  =1678 (C=O), 3301 cm−1 (NH); 
MS (ESI): m/z: calcd for C23H28Cl3N3O2: 483.1; found: 484.1 [M+H]+; elemental analysis calcd 
(%) for C23H28Cl3N3O2: C 56.99, H 5.80, N 8.64; found: C 56.90, H 5.82, N 8.67. 
 
Compound 13 (48 mg, 10 %), colorless oil. Rf=0.53 (petroleum ether/EtOAc 85:15); 1H NMR 
(400 MHz, CDCl3): δ=9.52 (d, J=8.0 Hz, 1 H; NH, exchanged with D2O), 8.63 (d, J=5.3 Hz, 
1 H), 7.99 (s, 1 H), 7.69–7.67 (m, 1 H), 7.46–7.40 (m, 1 H), 4.33 (dd, J=13.1, 5.7 Hz, 2 H), 3.94–
3.83 (m, 1 H), 3.51–3.40 (m, 2 H), 2.09–1.88 (m, 4 H), 1.80–1.72 (m, 2 H), 1.70–1.58 (m, 6 H), 
1.35–1.23 (m, 3 H), 0.91 ppm (d, J=6.5 Hz, 3 H); 13C NMR (101 MHz, CDCl3): δ=159.44 (C), 
158.92 (C), 141.68 (C), 133.11 (C), 133.05 (C), 132.22 (C), 129.79 (CH), 129.22 (CH), 128.80 
(C), 126.69 (CH), 124.03 (CH), 69.26 (CH2), 51.90 (CH2), 42.72 (CH), 29.00 (2×CH2), 28.30 
(2×CH2), 28.25 (CH), 28.09 (CH2), 27.33 (CH2), 22.42 (CH2), 13.52 ppm (CH3); IR:  =1673 
(C=O), 3298 cm−1 (NH); MS (ESI): m/z: calcd for C23H28Cl3N3O2: 483.1; found: 484.2 [M+H]+; 
elemental analysis calcd (%) for C23H28Cl3N3O2: C 56.98, H 5.82, N 8.67; found: C 57.05, H 
5.83, N 8.65. 
 
See the Supporting Information for compounds 14–16. 
 
6‐(5‐Bromothiophen‐2‐yl)‐2‐(4‐fluorobenzyl)‐cis‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2,3‐
dihydropyridazine‐4‐carboxamide (17) and 6‐(5‐bromothiophen‐2‐yl)‐2‐(4‐fluorobenzyl)‐
trans‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2,3‐dihydropyridazine‐4‐carboxamide (18): 4‐
Methylcyclohexylamine and 48 were reacted according to general procedure B to afford the title 
products. The cis/trans isomers were separated by flash chromatography (petroleum ether/EtOAc 
85:15). 
 
Compound 17 (90 mg, 19 %), yellow solid. Rf=0.30 (petroleum ether/EtOAc 85:15); m.p.: 158–
159 °C; 1H NMR (400 MHz, CDCl3): δ=9.81 (d, J=7.7 Hz, 1 H; NH, exchanged with D2O), 8.50 
(s, 1 H), 7.52–7.44 (m, 2 H), 7.23 (d, J=4.0 Hz, 1 H), 7.04 (t, J=6.5 Hz, 3 H), 5.36 (s, 2 H), 4.33–
4.13 (m, 1 H), 1.86–1.76 (m, 2 H), 1.70–1.56 (m, 4 H), 1.32–1.20 (m, 3 H), 0.97 ppm (d, J=6.5 
Hz, 3 H); 13C NMR (101 MHz, CDCl3): δ=162.94 (CF), 160.48 (CF), 159.32 (C), 158.48 (C), 
140.00 (C), 138.99 (C), 130.07 (C), 129.98 (CH), 129.91 (CH), 129.90 (CH), 129.21 (C), 128.90 
(CH), 125.42 (CH), 115.07 (C), 114.73 (CH), 114.52 (CH), 53.96 (CH2), 44.94 (CH), 29.96 
(CH), 29.04 (2×CH2), 28.42 (2×CH2), 20.48 ppm (CH3); IR:  =1683 (C=O), 3308 cm−1 (NH); 
MS (ESI): m/z: calcd for C23H23BrFN3O2S: 503.1; found: 504.2 [M+H]+; elemental analysis 
calcd (%) for C23H23BrFN3O2S: C 54.77, H 4.60, N 8.33; found: C 54.88, H 4.61, N 8.34. 
 
Compound 18 (55 mg, 11 %), yellow solid. Rf=0.48 (petroleum ether/EtOAc 85:15); m.p.: 140–
412 °C; 1H NMR (400 MHz, CDCl3): δ=9.42 (d, J=8.1 Hz, 1 H; NH, exchanged with D2O), 8.50 
(s, 1 H), 7.51–7.43 (m, 2 H), 7.24 (d, J=4.0 Hz, 1 H), 7.09–7.00 (m, 3 H), 5.34 (s, 2 H), 3.94–
3.75 (m, 1 H), 2.07–2.00 (m, 2 H), 1.80–1.71 (m, 2 H), 1.62–1.58 (m, 1 H), 1.41–1.23 (m, 2 H), 
1.15–1.01 (m, 2 H), 0.91 ppm (d, J=6.6 Hz, 3 H); 13C NMR (101 MHz, CDCl3): δ=162.93 (CF), 
160.47 (CF), 159.32 (C), 158.38 (C), 140.06 (C), 138.94 (C), 129.98 (C), 129.92 (CH), 129.85 
(CH), 129.77 (CH), 129.15 (C), 129.07 (CH), 125.47 (CH), 115.12 (C), 114.77 (CH), 114.55 
(CH), 54.23 (CH2), 48.09 (CH), 32.76 (2×CH2), 31.74 (2×CH2), 30.89 (CH), 21.16 ppm (CH3); 
IR:  =1681 (C=O), 3305 cm−1 (NH); MS (ESI): m/z: calcd for C23H23BrFN3O2S: 503.1; found: 
504.2 [M+H]+; elemental analysis calcd (%) for C23H23BrFN3O2S: C 54.77, H 4.60, N 8.33; 
found: C 54.85, H 4.59, N 8.34. 
 
See the Supporting Information for compounds 19–21. 
 
6‐(4‐Chloro‐3‐methylphenyl)‐cis‐N‐(4‐methylcyclohexyl)‐3‐oxo‐2‐pentyl‐2,3‐
dihydropyridazine‐4‐carboxamide (22): 4‐Methylcyclohexylamine and 44 were reacted 
according to general procedure A to afford the title products. The reaction mixture was stirred for 
18 h, then the crude material was purified by flash chromatography (petroleum ether/EtOAc 
95:5) to afford 22 (98 mg, 23 %) as a colorless oil. Rf=0.22 (petroleum ether/EtOAc 95:5); 1H 
NMR (400 MHz, CDCl3): δ=9.96 (d, J=7.8 Hz, 1 H; NH, exchanged with D2O), 8.65 (s, 1 H), 
7.73 (s, 1 H), 7.64 (d, J=8.3, 2.3 Hz, 1 H), 7.43 (d, J=8.3 Hz, 1 H), 4.33 (t, J=7.6 Hz, 2 H), 4.27–
4.19 (m, 1 H), 2.45 (s, 3 H), 2.19–2.02 (m, 1 H), 1.98–1.79 (m, 3 H), 1.80–1.55 (m, 4 H), 1.51–
1.22 (m, 7 H), 0.97 (d, J=6.5 Hz, 3 H), 0.92 ppm (t, J=6.3 Hz, 3 H); 13C NMR (101 MHz, 
CDCl3): δ=159.91 (C), 158.95 (C), 143.16 (C), 135.83 (C), 135.04 (C), 131.81 (C), 129.88 (CH), 
128.67 (CH), 128.50 (C), 127.35 (CH), 123.61 (CH), 51.88 (CH2), 44.79 (CH), 30.10 (CH), 
29.08 (2×CH2), 28.51 (2×CH2), 27.77 (CH2), 27.18 (CH2), 21.31 (CH2), 19.19 (2×CH3), 12.94 
ppm (CH3); IR:  =1683 (C=O), 3261 cm−1 (NH); MS (ESI): m/z: calcd for C24H32ClN3O2: 
429.2; found: 430.1 [M+H]+; elemental analysis calcd (%) for C24H32ClN3O2: C 67.04, H 7.50, N 
9.77; found: C 66.93, H 7.48, N 9.80. 
 
See the Supporting Information for compounds 23 and 24. 
 
Biological assays 
 
Radioligand binding assays at hCB1Rs and hCB2Rs: [3H]CP 55,940 (specific activity, 180 
Ci mmol−1) and CHO cells transfected with hCB1R and hCB2R were purchased from 
PerkinElmer Life and Analytical Sciences. All other reagents were obtained from Sigma (Milan, 
Italy). CHO cells expressing CB1R and CB2R were cultured in Ham's F12 supplemented with 
10 % fetal bovine serum, penicillin (100 U mL−1), streptomycin (100 μg mL−1), and geneticin 
(G418, 0.4 mg mL−1) at 37 °C in air containing 5 % CO2.41 Membranes from transfected cells to 
be used in binding experiments were obtained as previously reported.41 In brief, the cells were 
detached in ice‐cold hypotonic buffer (5 mm Tris‐HCl, 2 mm EDTA, pH 7.4), triturated with a 
Polytron and centrifuged for 10 min at 1000 g. Then the supernatant was centrifuged for 30 min 
at 100 000 g and the membrane pellet was diluted in 50 mm Tris‐HCl buffer, 0.5 % BSA (pH 
7.4) containing 5 mm MgCl2, 2.5 mm EDTA or 1 mm EDTA for hCB1R or hCB2R, respectively. 
Competition binding experiments were carried out with [3H]CP 55,940 in the presence of ligands 
under examination in the concentration range 1 nm to 10 μm or WIN 55,212‐2, the CB1R/CB2R 
standard agonist. Incubation times were 90 or 60 min at 30 °C for CB1Rs or CB2Rs, respectively. 
Bound and free radioactivities were separated by filtering the assay mixture through Whatman 
GF/C glass fiber filters using a Brandel cell harvester (Brandel Instruments, Unterföhring, 
Germany). The filter‐bound radioactivity was counted on a PerkinElmer 2810 TR scintillation 
counter (PerkinElmer Life and Analytical Sciences). 
 
cAMP assays for hCB2Rs: CHO cells expressing hCB2Rs were preincubated with the 
phosphodiesterase inhibitor 4‐(3‐butoxy‐4‐methoxybenzyl)‐2‐imidazolidinone (Ro 20–1724, 0.5 
mm). Then, the effect of a selection of compounds characterized by high affinity and selectivity 
toward CB2Rs was tested at increasing concentrations (0.001–1 μm) with or without 
WIN 55,212‐2 (0.1 μm) in the presence of forskolin (5 μm), by using the fluorimetric cAMP kit 
(AlphaScreen cAMP assay kit, PerkinElmer) according to the manufacturer's instructions. 
 
Data analysis: The protein concentration was measured by a Bio‐Rad method42 with bovine 
albumin as reference standard. Inhibitory binding constants Ki were obtained from the 
IC50 values following the Cheng and Prusoff equation: Ki=IC50/(1+[C]/KD), where [C] is the 
concentration of the radioligand and KD its dissociation constant (Cheng–Prusoff).22 A weighted 
nonlinear least‐squares curve fitting program, LIGAND, was used for computer analysis of the 
inhibition experiments.43 All the data are presented as the mean±SEM of n=4 independent 
experiments. Statistical analysis of the data was performed using ANOVA followed by Dunnett's 
test. 
 
Computational studies 
 
Conformational analysis: The Ballesteros–Weinstein numbering system for GPCR amino acid 
residues is used. In this numbering system, the label 0.50 is assigned to the most highly 
conserved residue in class A GPCRs in each transmembrane helix (TMH).44 This is preceded by 
the TMH number. In this system, for example, the most highly conserved residue in TMH6 is 
P6.50. The residue immediately before this would be labeled 6.49, and the residue immediately 
after this would be labeled 6.51. In reference to a specific CB2R residue, the Ballesteros–
Weinstein name is followed by the absolute sequence number given in parentheses [e.g., 
K3.28(109)]; however, if referring to a highly conserved residue among class A GPCRs (and not 
a specific residue in CB2R), only the Ballesteros–Weinstein name is given. 
 
A complete conformational analysis of 22 was performed using the Mixed Torsional/Low‐Mode 
Sampling technique as encoded in Macromodel (version 11.6, Schrödinger, LLC, New York, 
NY). Torsional moves of 30° or greater were set for all rotatable bonds within 22, including full 
exploration of the 4‐cis‐cyclohexyl ring. The search was comprised of 20 000 Monte Carlo steps 
using the OPLS3 force field with a distance‐dependent dielectric and a dielectric base constant of 
2. An 8.0 Å nonbonded cutoff (updated every 10 steps), a 20.0 Å electrostatic cutoff, and a 4.0 Å 
hydrogen‐bond cutoff were applied to the minimization of each conformation with a gradient of 
0.01 kcal mol−1 Å. Duplicate conformations identified at an RMSD≤0.7 were removed. To 
calculate the energy difference between the global minimal energy conformer of 22 and its final 
docked conformation, the single‐point energy of each was calculated in OPLS3 and the 
difference was calculated. 
 
Model development: Complete details on the generation of the CB2R inactive‐state model used 
here are available in our previous publication.25 In brief, the crystal structure of the class A 
GPCR rhodopsin in the dark state was used as the template for the creation of our CB2R inactive‐
state model.45 This template was chosen because no mutations or modifications were made to its 
structure for crystallization and there are no structural distortions due to crystal packing for this 
structure. In addition, the cannabinoid receptors and rhodopsin share some unusual sequence 
motifs. For example, these receptors share a TMH4 GWNC motif at their extracellular ends. 
Here a Trp residue forms an aromatic stacking interaction with Y5.39, influencing the 
extracellular positions of TMH3–4–5. The initial CB2R homology model was refined by 
calculating the low‐free‐energy conformations for any TMH with an important sequence 
divergence from rhodopsin and replacing the corresponding helix from the initial model with one 
that more accurately reflects the sequence‐dictated TMH geometries in CB2R. This includes 
TMH2 (a GG helix‐distorting motif in rhodopsin vs. no Pro or GG in CB2R) and TMH5 (Pro at 
5.50 in rhodopsin vs. no Pro at 5.50 in CB2R). This CB2R model has been tested using results 
from substituted cysteine‐accessibility studies to identify binding‐pocket‐facing 
residues,46, 47 from mutation studies of key ligand interactions sites,46-49 and from covalent 
labeling studies of CB2R that support a lipid‐entry pathway for CB2R ligands.50 To allow 
adjustment to a lipid bilayer environment, the resultant model was pre‐equilibrated in an SDPC 
bilayer for 300 ns.25 Although the toggle‐switch residue W6.48(258) remained in its inactive‐
state g+ χ1 dihedral angle after the equilibration in SDPC, some notable changes did occur 
during this equilibration. The R3.50(131)–D6.30(240) salt bridge at the intracellular ends of 
TMH3 and TMH6 (analogous to the R3.50(135)–E6.30(247) salt bridge in the dark state of 
rhodopsin) rearranged quickly to form a salt bridge between R3.55(136) and D6.30(240), with 
Y3.51(132) supporting the salt bridge by hydrogen bonding to the exposed backbone carbonyl of 
L6.29(239). A second notable change was the development of additional helical turns in the IC‐3 
(TMH5–TMH6) loop after the original end of TMH5.25 
 
Docking study in the CB2R inactive‐state model: Compound 22 was docked into the 
SR144528–CB2R binding site previously identified by Glide docking 
studies.23, 24, 26 Compound 22 was flexibly docked using Glide (version 7.5, Schrödinger) and the 
dock with the best Glide score, as ranked by Emodel, was chosen. Glide was used to generate a 
grid based on the centroid of select residues in the binding pocket. The box size was set to the 
default value of 24×24×24 Å, with the inner box size set to 10×10×10 Å. This box size 
encompasses the entire CB2R binding pocket both in width and depth. No scaling of van der 
Waals radii was used. S7.39(285) was defined to be a required interaction during the docking 
procedure, by analogy to literature mutation studies for binding of HU243 at the CB2R.51 Extra 
precision (XP) and flexible docking with 50 K maximum initial poses to be retained for the 
initial phase of docking were selected for the docking setup. During docking only trans amides 
were allowed, aromatic protons were set as donors and halogens as acceptors. After docking, a 
800‐step conjugate gradient minimization was performed on the ligand pose by Glide using 
OPLS3 (distance‐dependent dielectric with a base constant of 2). The resulting ligand–receptor 
complex with the best Glide score was minimized using the OPLS3 all‐atom force field in 
Macromodel. An 8.0 Å nonbonded cutoff (updated every 10 steps), a 20.0 Å electrostatic cutoff, 
and a 4.0 Å hydrogen‐bond cutoff were used in each stage of the calculation. The first stage 
consisted of 4000 steps of Polak–Ribier conjugate gradient minimization using a distance‐
dependent dielectric function with a base constant of 2. No harmonic constraints were placed on 
the side chains, but 100 kJ mol−1 torsional constraints were applied to hold all the 
backbone φ/ψ torsion angles. During the second stage of 1000 steps, all torsional constraints 
were released. To relax the loops, an additional 1000‐step Polak–Ribier conjugate gradient 
minimization of the loop regions was performed. The loop and termini regions were left free, 
whereas the transmembrane regions were not allowed to move during this final minimization. An 
8.0 Å extended nonbonded cutoff (updated every 10 steps), 20.0 Å electrostatic cutoff, and 4.0 Å 
hydrogen‐bond cutoff were used in this calculation, and the generalized Born/surface area 
(GB/SA) continuum solvation model for water available in Macromodel was used. 
 
Assessment of pairwise interaction energies: After the atoms of 22 had been defined as one 
group (group 1) and the atoms corresponding to a residue that lines the binding site in the final 
ligand–CB2R complex as another group (group 2), Macromodel was used to output the pairwise 
interaction energies (coulombic and van der Waals) for a given pair of atoms. The pairs 
corresponding to group 1 (ligand) and group 2 (residue of interest) were then summed to yield 
the energy of interaction between the ligand and that residue. The 22–CB2R complex was found 
to have interaction energies totaling −66.59 kcal mol−1. Taking the conformational energy cost 
for 22 in the final complex (0.89 kcal mol−1) into account, we found the final total energy for 
the 22–CB2R complex to be −65.70 kcal mol−1. A breakdown of interaction energies is provided 
in Table S1. 
 
In silico ADMET calculations: A set of 34 physicochemical descriptors were computed using 
QikProp version 3.5 integrated in Maestro (Schrödinger). The QikProp descriptors are shown in 
Table 2. The 3D conformations used in the calculation of QikProp descriptors were generated 
using the OPLS3 force field and the Mixed Torsional Low Mode Sampling Monte Carlo 
Conformational Search method in Macromodel 11.3 (Schrödinger, 2016). Possible 
tautomerization and ionization states were calculated using Epik integrated in the Maestro 
software. No tautomers were found for pyridazinones 2–24. Toxicity and metabolism predictions 
were performed by using the admetSAR prediction tool 
(http://lmmd.ecust.edu.cn/admetsar1/).34 Tables S2 and S3 summarize the parameters 
calculated and classify the compounds according to previously reported methods (see the 
Supporting Information). 
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Synthetic procedures and data for compounds 30, 32, 33, 35, 36, 38, 39, 41-44, 46 – 49, 4 
– 6, 9 – 11, 14 – 16, 19 – 21, 23 and 24. 
General Procedure for the preparation of acyl bromides (28-30) 
Method A: Bromine (3.02 mL, 59,3 mmol, 1 eq) was dropwise added to a stirred solution 
of appropriate ketone (59.3 mmol, 1 eq) in glacial AcOH (65 mL), the resulting solution 
was stirred at room temperature for 8 h. Then ice-water was poured into reaction flask and 
the resulting precipitate was filtered off, washed with H2O, and air-dried. The resulting 
crude product was purified by column flash chromatography using the appropriate eluents. 
Bromo-1-(4-chloro-3-methylphenyl)ethan-1-one (30): Following method A, ketone 27 
led to obtain a yellow solid which was purified by flash chromatography (petroleum 
ether/EtOAc 95:5) to afford 30 as a white solid (14.6 g, 95%), Rf =0.71 (petroleum 
ether/EtOAc 9:1); mp 60-61 °C; 1H NMR (400 MHz, Chloroform-d) δ 7.61 (s, 1H), 7.49 (d, 
J = 8.2 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 4.56 (s, 2H), 2.40 (s, 3H). 
General Procedure for the preparation of ketodiester derivatives (31-33). To a 
suspension of NaH (60% dispersion in mineral oil, 0.480 g, 20 mmol, 2 eq) in anhydrous 
THF (26 mL) was added dropwiswe a solution of diethylmalonate (1.83 mL, 12 mmol, 1.2 
eq) in anhydrous THF (6.5 mL) under N2 flow at 0 °C, and the mixture was stirred for 1 h. 
Then a solution of bromoketone (10 mmol, 1eq) in anhydrous THF (4 mL) was added 
dropwise and the resulting mixture of reaction was stirred at room temperature until 
complete conversion of the starting materials (TLC). The reaction was quenched with 
saturated NH4Cl aqueous solution, and the aqueous layer extracted with EtOAc. The 
combined organic layers were washed with H2O and brine, then dried over Na2SO4. The 
solvent was removed under reduced pressure and the resulting residue was purified by 
column flash chromatography with the appropriate eluents. 
Diethyl 2-[2-oxo-2-(thiophen-2-yl)ethyl]malonate (32): A mixture of diethylmalonate, 
NaH and 29 was stirred at room temperature for 24 h. The crude product of reaction was 
purified by flash chromatography (petroleum ether/EtOAc 8:2) to afford 32 as an orange oil 
(1.90 g, 67%), Rf = 0.21 (petroleum ether/EtOAc 9:1); 1H NMR (400 MHz, Chloroform-d) δ 
7.76 (t, J = 2.8 Hz, 1H), 7.64 (d, J = 4.4 Hz, 1H), 7.14 – 7.10 (m, 1H), 4.25 – 4.16 (m, 4H), 
4.02 (t, J = 7.0 Hz, 1H), 3.54 (d, J = 7.4 Hz, 2H), 1.26 (t, J = 6.8 Hz, 6H). 
Diethyl 2-(2-(4-chloro-3-methylphenyl)-2-oxoethyl)malonate (33): A mixture of 
diethylmalonate, NaH and 30 was stirred at room temperature for 24 h. The crude product 
of reaction was purified by flash chromatography (petroleum ether/EtOAc 95:5) to afford 
33 as a light yellow oil (1.79 g, 55%), Rf = 0.43 (petroleum ether/EtOAc 9:1);1H NMR (400 
MHz, Chloroform-d) δ 7.61 (s, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 4.28 
– 4.19 (m, 4H), 4.09 – 4.01 (m, 1H), 3.63 (d, J = 7.1 Hz, 2H), 2.40 (s, 3H), 1.34 – 1.22 (m, 
9H). 
General procedure for the preparation of dihydropyridazinone derivatives (34-36). To 
an ice-bath cooled solution of malonate derivatives 31-33 (15 mmol, 1 eq) in absolute 
ethanol (75 mL), hydrazine monohydrate 64-65% (0.79 mL, 16.5 mmol, 1.1 eq) was added 
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dropwise. The resulting solution was warmed to room temperature, then refluxed for 24 h. 
The solution was allowed to stand at room temperature and the resulting precipitate was 
isolated by filtration in vacuum, washed with cold water, and dried to air. The obtained 
solid was purified by column flash chromatography using the appropriate eluents. 
Ethyl 3-oxo-6-(thiophen-2-yl)-2,3,4,5-tetrahydropyridazine-4-carboxylate (35): From 
32 was obtained a solid which was purified by flash chromatography (petroleum 
ether/EtOAc 6:4) to give 35 as a white solid (2.6 g, 70%). Rf = 0.43 (petroleum 
ether/EtOAc 6:4); mp 150-151 °C;  1H NMR (400 MHz, Chloroform-d) δ 8.65 (s, 1H, NH, 
exch. with D2O), 7.40 (d, J = 4.9 Hz, 1H), 7.31 (t, J = 2.7 Hz, 1H), 7.10 – 7.03 (m, 1H), 
4.26 (q, J = 7.0 Hz, 2H), 3.61 (t, J = 7.8 Hz, 1H), 3.42 (dd, J = 16.8, 8.8 Hz, 1H), 3.12 (dd, 
J = 16.8, 6.9 Hz, 1H), 1.28 (t, J = 7.1 Hz, 3H). 
Ethyl 5-(4-chloro-3-methylphenyl)-2-oxo-1,2,3,4-tetrahydropyridine-3-carboxylate 
(36): From 33 was obtained a solid which was purified by flash chromatography 
(petroleum ether/EtOAc 7:3) to give 36 as a pale yellow solid (2.24 g, 52%). Rf = 0.32 
(petroleum ether/EtOAc 7:3); mp 164-165 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 
1H, NH, exch. with D2O), 7.61 (s, 1H), 7.49 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 
4.25 (q, J = 7.0 Hz, 2H), 3.60 (t, J = 7.6 Hz, 1H), 3.41 (dd, J = 16.9, 8.2 Hz, 1H), 3.07 (dd, 
J = 17.0, 6.9 Hz, 1H), 2.41 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H).  
General procedure for the preparation of pyridazinone derivatives (37-39). To a 
stirred solution of dihydropyridazinone 34-36 (5 mmol, 1 eq) in glacial AcOH (30 mL) was 
added dropwise (30 min) a solution of bromine (0.51 mL, 10 mmol, 2 eq) in glacial AcOH 
(8 mL). The resulting mixture was stirred at room temperature for 6-8 h. Then the solution 
was poured into ice-water, and aqueous solution was extracted with a separatory funnel 
with EtOAc. The collected organic phases were washed with H2O, saturated NaHCO3 
solution and brine. Then, dried (Na2SO4) and concentrated under reduced pressure to 
yield a residue which was purified by column flash chromatography using the appropriate 
eluents. 
Ethyl 6-(5-bromothiophen-2-yl)-3-oxo-2,3-dihydropyridazine-4-carboxylate (38): 
General procedure for the preparation of pyridazinones was used to oxidize 35. . The 
reaction mixture was stirred for 8 h and the obtained crude product purified by flash 
chromatography (petroleum ether/EtOAc 6:4) to afford 38 as a yellow solid (0.72 g, 44%). 
Rf = 0.26 (petroleum ether/EtOAc 6:4); mp 179-182 °C; 1H NMR (400 MHz, Chloroform-d) 
δ 11.55 (s, 1H, NH, exch. with D2O), 8.13 (s, 1H), 7.18 (t, J = 3.0 Hz, 1H), 7.06 (t, J = 3.1 
Hz, 1H), 4.46 (q, J = 6.9 Hz, 2H), 1.43 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
162.75 (C), 157.72 (C), 140.94 (C), 140.78 (C), 139.58 (C), 131.85 (CH), 130.79 (CH), 
126.13 (CH), 116.26 (C), 62.58 (CH2), 14.19 (CH3). 
Ethyl 6-(4-chloro-3-methylphenyl)-3-oxo-2,3-dihydropyridazine-4-carboxylate (39): 
General procedure for the preparation of pyridazinones was used to oxidize 36. . The 
reaction mixture was stirred for 8 h and the obtained crude product purified by flash 
chromatography (petroleum ether/EtOAc 4:6) to afford 39 as a pale yellow solid (0.8 g, 
55%). Rf = 0.33 (petroleum ether/EtOAc 1:1); mp 183-185 °C; 1H NMR (400 MHz, 
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Chloroform-d) δ 8.27 (s, 1H), 7.70 (s, 1H), 7.57 (d, J = 8.4 Hz, 1H), 7.44 (d, J = 8.3 Hz, 
1H), 4.47 (q, J = 7.1 Hz, 2H), 2.45 (s, 3H), 1.44 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, 
Chloroform-d) δ 163.06 (C), 158.53 (C), 144.50 (C), 137.02 (C), 136.33 (C), 133.15 (CH), 
132.26 (C), 130.53 (C), 129.76 (CH), 128.29 (CH), 124.52 (CH), 62.48 (CH2), 20.22 (CH3), 
14.23 (CH3). 
General procedure for the preparation of N-alkyl pyridazinone derivatives (40-44). To 
a solution of pyridazinones 37-39 (4 mmol, 1 eq) in anhydrous DMF (18 mL) was added 
K2CO3 (1.65 g, 12 mmol, 3 eq) and then the suitable alkyl/benzyl halide (12 mmol, 3 eq). 
The resulting suspension was underwent to ultrasound irradiation for 2 h at room 
temperature. Then the mixture of reaction was poured into ice-water, filtered off, and 
extracted with EtOAc in a separatory funnel. The collected organic phases were washed 
with H2O, LiCl 5% solution and brine, then dried (Na2SO4) and concentrated under 
reduced pressure. Resulting residue was purified by column flash chromatography using 
the appropriate eluents. 
Ethyl 2-(cyclohexylmethyl)-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyridazine-4-
carboxylate (41): From pyridazinone 37 and (bromomethyl)cyclohexane  was obtained a 
residue wihich was purified by flash chromatography (petroleum ether/EtOAc 8:2) to obtain 
41 as a pale yellow solid (1.3 g, 77%), Rf = 0.38 (petroleum ether/EtOAc 8:2), mp 94-95 
°C; 1H NMR (400 MHz, Chloroform-d) δ 8.15 (s, 1H), 7.90 (s, 1H), 7.63 (d, J = 8.3 Hz, 1H), 
7.54 (d, J = 8.3 Hz, 1H), 4.44 (q, J = 7.0 Hz, 2H), 4.14 (d, J = 7.1 Hz, 2H), 2.09 – 1.99 (m, 
1H), 1.85 – 1.56 (m, 5H), 1.42 (t, J = 7.0 Hz, 3H), 1.33 – 1.02 (m, 5H); 13C NMR (101 MHz, 
CDCl3) δ 163.71 (C), 156.71 (C), 140.61 (C), 134.22 (C), 133.82 (C), 133.51 (C), 130.98 
(CH), 130.90 (CH), 130.05 (C), 127.57 (CH), 124.79 (CH), 62.42 (CH2), 59.05 (CH2), 36.88 
(CH), 30.61 (CH2 x2), 26.27 (CH2), 25.65 (CH2 x2), 14.21 (CH3). 
Ethyl 2-(5-chloropentyl)-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyridazine-4-
carboxylate (42): From pyridazinone 37 and 1,5-dichloropentane was obtained a residue 
which was purified by flash chromatography (petroleum ether/EtOAc 8:2) to obtain 42 as 
an orange oil (1.0 g, 53%), Rf = 0.50 (petroleum ether/EtOAc 7:3); 1H NMR (400 MHz, 
Chloroform-d) δ 8.15 (s, 1H), 7.91 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.1 Hz, 
1H), 4.44 (q, J = 6.7 Hz, 2H), 4.30 (t, J = 7.0 Hz, 2H), 3.54 (t, J = 6.1 Hz, 2H), 1.98 – 1.78 
(m, 4H), 1.62 – 1.51 (m, 2H), 1.42 (t, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 163.54 
(C), 156.42 (C), 141.11 (C), 134.07 (C), 133.95 (C), 133.55 (C), 131.08, 131.00 (CH), 
130.21 (C), 127.60 (CH), 127.60 (CH), 124.80 (CH), 62.44 (CH2), 52.78 (CH2), 44.67 
(CH2), 32.04 (CH2), 27.60 (CH2), 23.91 (CH2), 14.20 (CH3). 
Ethyl 6-(5-bromothiophen-2-yl)-2-(4-fluorobenzyl)-3-oxo-2,3-dihydropyridazine-4-
carboxylate (43): From pyridazinone 38 and 4-fluorobenzylbromide was obtained a 
residue which was purified by flash chromatography (petroleum ether/EtOAc 7:3) to obtain 
43 as a yellow solid (1.39 g, 80%), Rf = 0.44 (petroleum ether/EtOAc 7:3), mp 123-125 °C; 
1H NMR (400 MHz, Chloroform-d) δ 8.02 (s, 1H), 7.49 (t, J = 8.1, 5.5 Hz, 2H), 7.13 (d, J = 
3.9 Hz, 1H), 7.05 – 6.98 (m, 3H), 5.31 (s, 2H), 4.42 (q, J = 7.1 Hz, 2H), 1.40 (t, J = 7.1 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 163.92 (C), 163.23 (CF), 161.26 (CF), 156.02 (C), 
139.95 (C), 139.27 (C), 138.31 (C) 131.21 (CH), 131.13 (CH), 130.79 (CH), 130.60 (C), 
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130.38 (CH), 125.72 (CH), 115.92 (C), 115.66 (CH), 115.45 (CH), 62.47 (CH2), 55.24 
(CH2), 14.19 (CH3). 
Ethyl 6-(4-chloro-3-methylphenyl)-3-oxo-2-pentyl-2,3-dihydropyridazine-4-
carboxylate (44): From pyridazinone 39 and pentylchloride was obtained a residue which 
was purified by flash chromatography (petroleum ether/EtOAc 8:2) to obtain 44 as a yellow 
oil (1.2 g, 85%), Rf = 0.36 (petroleum ether/EtOAc 8:2); 1H NMR (400 MHz, Chloroform-d) 
δ 8.16 (s, 1H), 7.67 (s, 1H), 7.56 (d, J = 8.2 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 4.45 (q, J = 
7.1 Hz, 2H), 4.29 (t, J = 7.4 Hz, 2H), 2.46 (s, 3H), 1.95 – 1.82 (m, 2H), 1.49 – 1.34 (m, 7H), 
0.91 (t, J = 6.2 Hz, 3H); 13C NMR (101 MHz, Chloroform-d) δ 163.94 (C), 156.54 (C), 
142.41 (C), 136.88 (C), 135.92 (C), 132.79 (C), 131.41 (CH), 129.97 (C), 129.68 (CH), 
128.11 (CH), 124.41 (CH), 62.32 (CH2), 53.02 (CH2), 28.79 (CH2), 28.10 (CH2), 20.24 
(CH3), 14.22 (CH3), 13.95 (CH3). 
General procedure for the preparation of pyridazinone carboxilic acid derivatives 
45-49. To a stirred solution of pyridazinone ethyl ester (3 mmol) in EtOH (50 mL), a 
solution of NaOH 2 M (50 mL) was added. The resulting mixture was heated to reflux and 
stirred for overnight. Then the solution was allowed to cool at room temperature and 
acidified with HCl 6M. The resulting precipitate was filtered under vacuum, washed with 
H2O and air-dried to yield the analytically pure acid. 
2-(Cyclohexylmethyl)-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxy-
lic acid (46): alkaline saponification in hydroalcoholic NaOH of pyridazinone ethyl ester 41 
furnished acid 46 as a white solid (1.0 g, 89%), Rf = 0.47 (CHCl3/MeOH 95:5); mp 199-201 
°C; 1H NMR (400 MHz, Chloroform-d) δ 14.01 (s, 1H), 8.61 (s, 1H), 7.98 (s, 1H), 7.68 (d, J 
= 8.2 Hz, 1H), 7.59 (d, J = 8.3 Hz, 1H), 4.24 (d, J = 7.0 Hz, 2H), 2.10 – 1.98 (m, 1H), 1.81 
– 1.63 (m, 6H), 1.32 – 1.06 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 163.15 (C), 161.94 (C), 
144.00 (C), 134.96 (C), 133.91 (C), 133.18 (C), 132.35 (CH), 131.26 (CH), 127.95 (CH), 
126.10 (C), 125.10 (CH), 59.20 (CH2), 37.19 (CH), 30.47 (CH2 x2), 26.10 (CH2), 25.54 
(CH2 x2). 
2-(5-Chloropentyl)-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxylic 
acid (47): alkaline saponification in hydroalcoholic NaOH of pyridazinone ethyl ester 42 
furnished acid 47 as a light yellow solid (0.99 g, 85%), Rf = 0.44 (CHCl3/MeOH 9:1); mp 
102-104 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.61 (s, 1H), 7.98 (s, 1H), 7.68 (d, J = 8.5 
Hz, 1H), 7.58 (d, J = 8.3 Hz, 1H), 4.40 (q, J = 6.5 Hz, 2H), 3.50 – 3.39 (m, 2H), 1.96 (h, J = 
7.3 Hz, 2H), 1.67 (p, J = 6.9 Hz, 2H), 1.50 (h, J = 8.0 Hz, 2H); 13C NMR (101 MHz, CDCl3) 
δ 163.09 (C), 161.65 (C), 144.30 (C), 134.99 (C), 133.90 (C), 133.11 (C), 132.51 (CH), 
131.26 (CH), 127.96 (CH), 126.16 (C), 125.12 (CH), 70.11 (CH2), 53.39 (CH2), 29.30 
(CH2), 28.25 (CH2), 23.36 (CH2). 
6-(5-Bromothiophen-2-yl)-2-(4-fluorobenzyl)-3-oxo-2,3-dihydropyridazine-4-carboxy-
lic acid (48): alkaline saponification in hydroalcoholic NaOH of pyridazinone ethyl ester 43 
furnished acid 48 as a yellow solid (1.1 g, 93%), Rf = 0.27 (CHCl3/MeOH 95:5); mp 214-
216 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.47 (s, 1H), 7.58 – 7.44 (m, 2H), 7.19 – 6.96 
(m, 4H), 5.40 (s, 2H); 13C NMR (101 MHz, CDCl3) δ 164.22 (CF), 162.70 (C), 161.76 (CF), 
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161.11 (C), 142.30 (C), 138.80 (C), 129.97 (C) 131.91 (CH), 131.28 (CH), 131.19 (CH x2), 
127.35 (CH), 126.56 (C), 117.48 (C), 116.04 (CH), 115.82 (CH), 55.7 (CH2). 
6-(4-Chloro-3-methylphenyl)-3-oxo-2-pentyl-2,3-dihydropyridazine-4-carboxylic acid 
(49): alkaline saponification in hydroalcoholic NaOH of pyridazinone ethyl ester 44 
furnished acid 49 as a pink solid (0.95 g, 94%), Rf = 0.59 (CHCl3/MeOH 9:1); mp 128-129 
°C; 1H NMR (400 MHz, Chloroform-d) δ 8.64 (s, 1H), 7.72 (s, 1H), 7.63 (d, J = 8.0 Hz, 1H), 
7.47 (d, J = 7.8 Hz, 1H), 4.37 (t, J = 7.6 Hz, 2H), 2.47 (s, 3H), 1.93 (s, 2H), 1.41-1.33 (m, 
4H), 0.93 (t, J = 6.2 Hz, 3H). 13C NMR (101 MHz Chloroform-d) δ 163.43 (C=O), 161.68 
(C=O), 145.74 (C), 137.26 (C), 136.97 (C), 132.88 (CH), 131.78 (C), 129.98 (CH), 128.47 
(CH), 125.92 (C), 124.75 (CH), 53.40 (CH2), 28.63 (CH2), 28.11 (CH2), 22.23 (CH2), 20.26 
(CH3), 13.90 (CH3). 
General procedures for the synthesis of carboxamide derivatives (2-24).  
Procedure A: To a stirred solution of acids 45-47, 49 (1 mmol, 1 eq) in DCM (10 mL), 
HOBt (0.20 g, 1.5 mmol, 1.5 eq) and EDC (0.38 g, 2 mmol, 2 eq) were added. The 
resulting mixture was stirred at room temperature for 30 min. Afterward a solution of 
suitable amine in DCM (10 mL) was added dropwise at 0 °C. The mixture of reaction was 
allowed to stand at room temperature, and then stirred for 12-24 h. The solution was then 
poured into a separatory funnel and H2O was added. The aqueous phase was separated, 
and extracted with DCM. The combined organic phases were washed with H2O and brine, 
dried (Na2SO4) and concentrated under reduced pressure. The analytically pure product 
was isolated by column flash chromatography purification using the appropriate eluents. 
Procedure B: A solution of acid 48 (410 mg, 1.0 mmol, 1 eq) and thionyl chloride (0.22 
mL, 3 mmol, 3 eq) in toluene (9 mL) was refluxed for 3 h. Then, the excess of thionyl 
chloride was removed under reduced pressure and the resulting dark solid was dissolved 
in DCM (15 mL). To a resulting solution was added dropwise at 0 °C a solution of 
appropriate amine (1.5 eq) and Et3N (1.5 eq) in DCM (15 mL).  The mixture of reaction 
was allowed to stand at room temperature and stirred for 12 h. Then the mixture was 
poured into a separatory funnel and H2O was added. The aqueous phase was separated 
and extracted with DCM. The combined organic phases were washed with H2O, dried 
(Na2SO4) and concentrated under reduced pressure. The analytically pure product was 
isolated by column flash chromatography purification using the appropriate eluents. 
N-Cyclohexyl-6-(3,4-dichlorophenyl)-2-(4-fluorobenzyl)-3-oxo-2,3-dihydropyridazine-
4-carboxamide (4): General procedure A for the synthesis of carboxamides was used to 
convert acid 45 and cyclohexylamine into the title products. The mixture of reaction was 
stirred for 16 h then the crude of reaction was purified by flash chromatography (petroleum 
ether/EtOAc 85:15) to afford 4 (137 mg, 29%), as an orange solid, Rf = 0.29 (petroleum 
ether/EtOAc 9:1); mp 125-127 °C; IR 1669 (C=O), 3380 (NH); 1H NMR (400 MHz, 
Chloroform-d) δ 9.50 (d, J = 8.0 Hz, 1H, NH, exch with D2O), 8.63 (s, 1H), 7.98 (s, 1H), 
7.68 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 6.8 Hz, 2H), 7.05 (t, J = 8.4 
Hz, 2H), 5.43 (s, 2H), 4.09 – 3.84 (m, 1H), 2.03 – 1.94 (m, 2H), 1.80 – 1.71 (m, 2H), 1.67 – 
1.58 (m, 2H), 1.50 – 1.20 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 163.95 (CF), 161.49 (CF), 
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160.27 (C), 159.65 (C), 143.19 (C), 134.24 (C), 133.98 (C), 133.59 (C), 131.08 (CH), 
131.04 (CH), 130.99 (C) 130.78 (CH), 130.70 (CH), 130.33 (C), 127.87 (CH), 125.09 (CH), 
115.83 (CH), 115.62 (CH), 55.76 (CH2), 48.64 (CH), 32.65 (CH2 x2), 25.58 (CH2), 24.63 
(CH2 x2); MS (ESI): C24H22FCl2N3O2 requires m/z 473.1, found 474.2 [M + 1]+; Anal. calcd 
for C24H22FCl2N3O2: C, 60.77; H, 4.67; N, 8.86; Found: C, 60.89; H, 4.68; N, 8.83. 
N-Cycloheptyl-6-(3,4-dichlorophenyl)-2-(4-fluorobenzyl)-3-oxo-2,3-dihydropyridazi-
ne-4-carboxamide (5): General procedure A for the synthesis of carboxamides was used 
to convert acid 45 and cycloheptylamine into the title products. The mixture of reaction was 
stirred for 16 h then the crude of reaction was purified by flash chromatography (petroleum 
ether/EtOAc 8:2) to afford 5 (240 mg, 50%), as an orange solid, Rf = 0.27 (petroleum 
ether/EtOAc 9:1); mp 127-129 °C; IR 1662 (C=O), 3376 (NH); 1H NMR (400 MHz, 
Chloroform-d) δ 9.56 (d, J = 8.0 Hz, 1H, NH, exch with D2O), 8.63 (s, 1H), 7.98 (s, 1H), 
7.68 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 6.4 Hz, 2H), 7.05 (t, J = 7.9 
Hz, 2H), 5.43 (s, 2H), 4.25 – 4.04 (m, 1H), 2.06 – 1.91 (m, 2H), 1.79 – 1.48 (m, 10H); 13C 
NMR (101 MHz, CDCl3) δ 162.93 (CF), 160.47 (CF), 159.01 (C), 158.63 (C), 142.16 (C), 
133.22 (C), 132.96 (C), 132.58 (C), 130.98 (C), 130.02 (CH), 130.00 (CH), 129.78 (CH), 
129.69 (CH), 129.33 (C), 126.84 (CH), 124.04 (CH), 114.81 (CH), 114.60 (CH), 54.71 
(CH2), 49.93 (CH), 33.68 (CH2 x2), 27.03 (CH2 x2), 23.11 (CH2 x2); MS (ESI): 
C25H24FCl2N3O2 requires m/z 487.1, found 488.1 [M + 1]+; Anal. calcd for C25H24FCl2N3O2: 
C, 61.48; H, 4.95; N, 8.60; Found: C, 61.33; H, 4.94; N, 8.61. 
N-(Adamantan-1-yl)-6-(3,4-dichlorophenyl)-2-(4-fluorobenzyl)-3-oxo-2,3-dihydropyri-
dazine-4-carboxamide (6): General procedure A for the synthesis of carboxamides was 
used to convert acid 45 and 1-adamantylamine into the title products. The mixture of 
reaction was stirred for 12 h then the crude of reaction was purified by flash 
chromatography (petroleum ether/EtOAc 85:15) to afford 6 (215 mg, 41%), as a white 
solid, Rf = 0.47 (petroleum ether/EtOAc 9:1); mp 175-176 °C; IR 1659 (C=O), 3330 (NH); 
1H NMR (400 MHz, Chloroform-d) δ 9.40 (br s, 1H, NH, exch with D2O), 8.61 (s, 1H), 7.97 
(s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 6.8 Hz, 2H), 7.04 (t, J 
= 8.3 Hz, 2H), 5.42 (s, 2H), 2.29 – 2.03 (m, 9H), 1.86 – 1.67 (m, 6H); 13C NMR (101 MHz, 
CDCl3) δ 162.91 (CF), 160.45 (CF), 158.75 (C x2), 142.13 (C), 142.06 (C), 133.17 (C), 
133.00 (C), 132.56 (C), 130.16 (C), 130.02 (CH), 129.77 (CH), 129.69 (CH x2), 126.81 
(CH), 123.96 (CH), 114.79 (CH), 114.57 (CH), 54.70 (CH2), 51.46 (C), 40.30 (CH2 x3), 
35.37 (CH2 x3), 28.40 (CH x3); MS (ESI): C28H26FCl2N3O2 requires m/z 525.1, found 526.1 
[M + 1]+; Anal. calcd for C28H26FCl2N3O2: C, 63.88; H, 4.98; N, 7.98; Found: C, 63.96; H, 
4.97; N, 7.96. 
N-Cyclohexyl-2-(cyclohexylmethyl)-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyrida-
zine-4-carboxamide (9): General procedure A for the synthesis of carboxamides was 
used to convert acid 46 and cyclohexylamine into the title products. The mixture of 
reaction was stirred for 18 h then the crude of reaction was purified by flash 
chromatography (petroleum ether/EtOAc 9:1) to afford 9 (115 mg, 25%), as a white solid, 
Rf = 0.35 (petroleum ether/EtOAc 9:1); mp 144-146 °C; IR 1677 (C=O), 3351 (NH); 1H 
NMR (400 MHz, Chloroform-d) δ 9.62 (d, J = 8.1 Hz, 1H, NH, exch. with D2O), 8.63 (s, 
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1H), 7.98 (s, 1H), 7.69 (d, J = 8.4 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 4.17 (d, J = 7.3 Hz, 
2H), 4.06 – 3.91 (m, 1H), 2.07 – 1.93 (m, 4H), 1.82 – 1.58 (m, 7H), 1.51 – 1.03 (m, 10H); 
13C NMR (101 MHz, CDCl3) δ 160.60 (C), 160.14 (C), 142.48 (C), 134.24 (C), 134.00 (C), 
133.53 (C), 130.98 (CH), 130.54 (CH), 129.69 (C), 127.82 (CH), 125.04 (CH), 58.95 (CH2), 
48.60 (CH), 36.94 (CH), 32.67 (CH2 x2), 30.58 (CH2 x2), 26.24 (CH2 x2), 25.63 (CH2 x2), 
24.64 (CH2 x2); MS (ESI): C24H29Cl2N3O2 requires m/z 461.2, found 462.1 [M + 1]+; Anal. 
calcd for C24H29Cl2N3O2: C, 62.34; H, 6.32; N, 9.09; Found: C, 62.21; H, 6.34; N, 9.06. 
N-Cycloheptyl-2-(cyclohexylmethyl)-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyrida-
zine-4-carboxamide (10): General procedure A for the synthesis of carboxamides was 
used to convert acid 46 and cycloheptylamine into the title products. The mixture of 
reaction was stirred for 18 h then the crude of reaction was purified by flash 
chromatography (petroleum ether/EtOAc 93:7) to afford 10 (85 mg, 18%), as a white solid, 
Rf = 0.25 (petroleum ether/EtOAc 9:1); mp 134-135 °C; IR 1667 (C=O), 3348 (NH); 1H 
NMR (400 MHz, Chloroform-d) δ 9.67 (d, J = 8.0 Hz, 1H, NH, exch. with D2O), 8.63 (s, 
1H), 7.98 (s, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 4.17 (d, J = 7.4 Hz, 
3H), 2.08 – 1.95 (m, 3H), 1.81 – 1.54 (m, 14H), 1.33 – 1.06 (m, 6H); 13C NMR (101 MHz, 
CDCl3) δ 159.35 (C), 159.12 (C), 141.45 (C), 133.24 (C), 132.98 (C), 132.52 (C), 129.97 
(CH), 129.47 (CH), 128.71 (C), 126.80 (CH), 124.00 (CH), 57.90 (CH2), 49.87 (CH), 35.93 
(CH), 33.71 (CH2 x2), 29.56 (CH2 x2), 27.09 (CH2), 25.22 (CH2 x2), 24.61 (CH2 x2), 23.11 
(CH2 x2); MS (ESI): C25H31Cl2N3O2 requires m/z 461.2, found 462.1 [M + 1]+; Anal. calcd 
for C25H31Cl2N3O2: C, 63.02; H, 6.56; N, 8.82; Found: C, 63.16; H, 6.58; N, 8.80. 
N-(Adamantan-1-yl)-2-(cyclohexylmethyl)-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydro-
pyridazine-4-carboxamide (11): General procedure A for the synthesis of carboxamides 
was used to convert acid 46 and 1-adamantylamine into the title products. The mixture of 
reaction was stirred for 16 h then the crude of reaction was purified by flash 
chromatography (petroleum ether/EtOAc 95:5) to afford 11 (210 mg, 41%), as a white 
solid, Rf = 0.54 (petroleum ether/EtOAc 9:1); mp 179-181 °C; IR 1682 (C=O), 3296 (NH); 
1H NMR (400 MHz, Chloroform-d) δ 9.51 (br s, 1H, NH, exch. with D2O), 8.62 (s, 1H), 7.97 
(s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 4.16 (d, J = 7.2 Hz, 2H), 2.19 – 
2.09 (m, 9H), 1.81 – 1.60 (m, 11H), 1.30 – 1.04 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 
160.25 (C), 160.08 (C), 142.43 (C), 134.28 (C), 133.95 (C), 133.52 (C), 130.98 (CH), 
130.53 (C), 130.17 (CH), 127.78 (CH), 124.93 (CH), 58.92 (CH2), 52.41 (C), 41.34 (CH2 
x3), 36.91 (CH), 36.41 (CH2 x3), 30.57 (CH2 x2), 29.43 (CH x3), 26.25 (CH2), 25.63 (CH2 
x2); MS (ESI): C28H33Cl2N3O2 requires m/z 513.1, found 414.2 [M + 1]+; Anal. calcd for 
C28H33Cl2N3O2: C, 65.37; H, 6.47; N, 8.17; Found: C, 65.44; H, 6.46; N, 8.15. 
2-(5-Chloropentyl)-N-cyclohexyl-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyridazine-
4-carboxamide (14): General procedure A for the synthesis of carboxamides was used to 
convert acid 47 and cyclohexylamine into the title products. The mixture of reaction was 
stirred for 24 h then the crude of reaction was purified by flash chromatography (petroleum 
ether/EtOAc 85:15) to afford 14 (70 mg, 15%), as a yellow oil, Rf = 0.27 (petroleum 
ether/EtOAc 9:1); IR 1668 (C=O), 3371 (NH); 1H NMR (400 MHz, Chloroform-d) δ 9.63 (d, 
J = 8.2 Hz, 1H, NH, exch. with D2O), 8.64 (s, 1H), 7.99 (s, 1H), 7.69 (d, J = 8.5 Hz, 1H), 
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7.55 (d, J = 9.0 Hz, 1H), 4.33 (t, J = 7.2 Hz, 2H), 4.04 – 3.94 (m, 1H), 3.52 – 3.39 (m, 4H), 
2.03 – 1.88 (m, 5H), 1.80 – 1.63 (m, 3H), 1.53 – 1.25 (m, 4H), 1.19 (t, J = 7.2 Hz, 2H); 13C 
NMR (101 MHz, CDCl3) δ 160.54 (C), 159.86 (C), 142.85 (C), 134.18 (C), 134.05 (C), 
133.55 (C), 130.99 (CH), 130.68 (CH), 129.75 (C), 127.84 (CH), 125.04 (CH), 70.25 (CH2), 
53.08 (CH2), 48.53 (CH), 32.64 (CH2 x2), 29.39 (CH2), 28.31 (CH2), 25.60 (CH2), 24.57 
(CH2 x2), 23.44 (CH2); MS (ESI): C22H26Cl3N3O2 requires m/z 469.1, found 470.2 [M + 1]+; 
Anal. calcd for C22H26Cl3N3O2: C, 56.12; H, 5.57; N, 8.93; Found: C, 56.20; H, 5.56; N, 
8.95. 
2-(5-Chloropentyl)-N-cycloheptyl-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyridazi-
ne-4-carboxamide (15): General procedure A for the synthesis of carboxamides was 
used to convert acid 47 and cycloheptylamine into the title products. The mixture of 
reaction was stirred for 24 h then the crude of reaction was purified by flash 
chromatography (petroleum ether/EtOAc 9:1) to afford 15 (135 mg, 28%), as a colourless 
oil, Rf = 0.29 (petroleum ether/EtOAc 9:1); IR 1658 (C=O), 3358 (NH); 1H NMR (400 MHz, 
Chloroform-d) δ 9.68 (d, J = 8.0 Hz, 1H, NH, exch. with D2O), 8.63 (s, 1H), 7.99 (d, J = 2.3 
Hz, 1H), 7.69 (d, J = 8.5 Hz, 1H), 7.55 (d, J = 8.4 Hz, 1H), 4.33 (t, J = 7.5 Hz, 2H), 4.22 – 
4.13 (m, 1H), 3.51 – 3.39 (m, 4H), 2.06 – 1.86 (m, 4H), 1.74 – 1.44 (m, 10H), 1.23 – 1.14 
(m, 2H); 13C NMR (101 MHz, CDCl3) δ 159.29 (C), 158.84 (C), 141.82 (C), 133.17 (C), 
133.02 (C), 132.53 (C), 129.97 (CH), 129.62 (CH), 128.76 (C), 126.82 (CH), 124.00 (CH), 
69.23 (CH2), 52.04 (CH2), 49.79 (CH2), 33.67 (CH2 x2), 28.38 (CH2), 27.30 (CH2), 27.08 
(CH2 x2), 23.07 (CH2 x2), 22.43 (CH2); MS (ESI): C23H28Cl3N3O2 requires m/z 483.1, found 
484.1 [M + 1]+; Anal. calcd for C23H28Cl3N3O2: C, 56.98; H, 5.82; N, 8.67;  Found: C, 56.85; 
H, 5.81; N, 8.70. 
N-(Adamantan-1-yl)-2-(5-chloropentyl)-6-(3,4-dichlorophenyl)-3-oxo-2,3-dihydropyri-
dazine-4-carboxamide (16): General procedure A for the synthesis of carboxamides was 
used to convert acid 47 and 1-adamantylamine into the title products. The mixture of 
reaction was stirred for 16 h then the crude of reaction was purified by flash 
chromatography (petroleum ether/EtOAc 9:1) to afford 16 (183 mg, 35%), as a white solid, 
Rf = 0.35 (petroleum ether/EtOAc 9:1); mp 80-82 °C; IR 1670 (C=O), 3348 (NH); 1H NMR 
(400 MHz, Chloroform-d) δ 9.51 (br s, 1H, NH, exch. with D2O), 8.61 (s, 1H), 7.98 (s, 1H), 
7.67 (d, J = 8.3 Hz, 1H), 7.53 (d, J = 8.4 Hz, 1H), 4.42 – 4.26 (m, 2H), 3.54 – 3.37 (m, 2H), 
2.21 – 2.06 (m, 9H), 2.00 – 1.85 (m, 2H), 1.81 – 1.61 (m, 6H), 1.56 – 1.43 (m, 2H), 1.27 – 
1.13 (m, 2H); 13C NMR (101 MHz, CDCl3) δ 158.95 (C), 141.79 (C), 133.26 (C), 133.20 
(C), 132.98 (C), 132.52 (C), 129.97 (CH), 129.62 (C), 129.29 (CH), 126.78 (CH), 123.91 
(CH), 69.24 (CH2), 52.07 (CH2), 51.39 (C), 40.34 (CH2 x3), 35.39 (CH2 x3), 28.41 (CH x3), 
28.37 (CH2), 27.29 (CH2), 22.41 (CH2); MS (ESI): C26H30Cl3N3O2 requires m/z 521.1, 
found 522.1 [M + 1]+; Anal. calcd for C26H30Cl3N3O2: C, 59.72; H, 5.78; N, 8.04;  Found: C, 
59.64; H, 5.77; N, 8.01. 
6-(5-Bromothiophen-2-yl)-N-cyclohexyl-2-(4-fluorobenzyl)-3-oxo-2,3-dihydropyridazi-
ne-4-carboxamide (19): General procedure B for the synthesis of carboxamides was 
used to convert acid 48 and cyclohexylamine into the title products. Purified by flash 
chromatography (petroleum ether/EtOAc 8:2) to afford 19 (240 mg, 49%), as a pale yellow 
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solid, Rf = 0.23 (petroleum ether/EtOAc 9:1); mp 137-140 °C; IR 1679 (C=O), 3340 (NH); 
1H NMR (400 MHz, Chloroform-d) δ 9.52 (d, J = 8.2 Hz, 1H, NH, exch with D2O), 8.50 (s, 
1H), 7.54 – 7.42 (m, 2H), 7.24 (d, J = 4.0 Hz, 1H), 7.07 – 7.01 (m, 3H), 5.34 (s, 2H), 4.03 – 
3.87 (m, 1H), 2.06 – 1.89 (m, 2H), 1.80 – 1.68 (m, 2H), 1.66 – 1.57 (m, 2H), 1.51 – 1.31 
(m, 4H); 13C NMR (101 MHz, CDCl3) δ 162.94 (CF), 160.48 (CF), 159.20 (C), 158.41 (C), 
140.05 (C), 138.96 (C), 130.01 (C), 129.92 (CH), 129.88 (CH), 129.80 (CH), 129.20 (C), 
129.06 (CH), 125.46 (CH), 115.11 (C), 114.76 (CH), 114.55 (CH), 54.18 (CH2), 47.63 
(CH), 31.62 (CH2 x2), 24.57 (CH2), 23.62 (CH2 x2); MS (ESI): C22H21BrFN3O2S requires 
m/z 489.0, found 490.0 [M + 1]+; Anal. calcd for C22H21BrFN3O2S: C, 53.88; H, 4.32; N, 
8.57; Found: C, 53.97; H, 4.31; N, 8.55. 
6-(5-Bromothiophen-2-yl)-N-cycloheptyl-2-(4-fluorobenzyl)-3-oxo-2,3-dihydropyrida-
zine-4-carboxamide (20): General procedure B for the synthesis of carboxamides was 
used to convert acid 48 and cycloheptylamine into the title products. Purified by flash 
chromatography (petroleum ether/EtOAc 9:1) to afford 20 (196 mg, 39%), as a yellow 
solid, Rf = 0.24 (petroleum ether/EtOAc 9:1); mp 151-152 °C; IR 1672 (C=O), 3331 (NH); 
1H NMR (400 MHz, Chloroform-d) δ 9.58 (d, J = 8.0 Hz, 1H, NH, exch with D2O), 8.50 (s, 
1H), 7.49 – 7.44 (m, 2H), 7.23 (d, J = 4.0 Hz, 1H), 7.07 – 7.01 (m, 3H), 5.34 (s, 2H), 4.30 – 
4.01 (m, 1H), 2.04 – 1.93 (m, 2H), 1.79 – 1.43 (m, 10H); 13C NMR (101 MHz, CDCl3) δ 
162.93 (CF), 160.48 (CF), 158.97 (C), 158.41 (C), 140.05 (C), 138.97 (C), 130.02 (C), 
129.92 (CH), 129.89 (CH), 129.81 (CH), 129.22 (C), 129.01 (CH), 125.43 (CH), 115.10 
(C), 114.76 (CH), 114.54 (CH), 54.14 (CH2), 49.93 (CH), 33.67 (CH2 x2), 27.03 (CH2 x2), 
23.12 (CH2 x2); MS (ESI): C23H23BrFN3O2S requires m/z 503.0, found 504.1 [M + 1]+; Anal. 
calcd for C23H23BrFN3O2S: C, 54.77; H, 4.60; N, 8.33; Found: C, 54.70; H, 4.61; N, 8.31. 
N-(Adamantan-1-yl)-6-(5-bromothiophen-2-yl)-2-(4-fluorobenzyl)-3-oxo-2,3-dihydro-
pyridazine-4-carboxamide (21): General procedure B for the synthesis of carboxamides 
was used to convert acid 48 and 1-adamantylamine into the title products. Purified by flash 
chromatography (petroleum ether/EtOAc 9:1) to afford 21 (217 mg, 40%), as a white solid, 
Rf = 0.25 (petroleum ether/EtOAc 95:5); mp 188-190 °C; IR 1664 (C=O), 3297 (NH); 1H 
NMR (400 MHz, Chloroform-d) δ 9.42 (br s, 1H, NH, exch with D2O), 8.48 (s, 1H), 7.51 – 
7.42 (m, 2H), 7.20 (d, J = 4.0 Hz, 1H), 7.08 – 6.98 (m, 3H), 5.33 (s, 2H), 2.15 – 2.11 (m, 
9H), 1.74 – 1.70 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 162.92 (CF), 160.47 (CF), 158.69 
(C), 158.53 (C), 140.04 (C), 139.04 (C), 130.06 (C), 130.02 (C), 129.93 (CH), 129.89 (CH), 
129.81 (CH), 128.70 (CH), 125.30 (CH), 115.04 (C), 114.74 (CH), 114.52 (CH), 54.14 
(CH2), 51.45 (C), 40.31 (CH2 x3), 35.38 (CH2 x3), 28.41 (CH x3); MS (ESI): 
C26H25BrFN3O2S requires m/z 541.1, found 542.1 [M + 1]+; Anal. calcd for 
C26H25BrFN3O2S: C, 57.57; H, 4.65; N, 7.75; Found: C, 57.63; H, 4.64; N, 7.77.  
6-(4-Chloro-3-methylphenyl)-N-cyclohexyl-3-oxo-2-pentyl-2,3-dihydropyridazine-4-
carboxamide (23): General procedure A for the synthesis of carboxamides was used to 
convert acid 44 and cyclohexylamine into the title product. The mixture of reaction was 
stirred for 16 h, then the crude of reaction was purified by flash chromatography 
(petroleum ether/EtOAc 9:1) to afford 23 (99 mg, 24%) as a colourless oil. Rf = 0.74 
(petroleum ether/EtOAc 8:2); IR 1676 (C=O), 3295 (NH); 1H NMR (400 MHz, Chloroform-
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d) δ 9.69 (d, J = 8.1 Hz, 1H, NH, exch. with D2O), 8.64 (s, 1H), 7.73 (s, 1H), 7.63 (d, J = 
8.3 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 4.31 (t, J = 7.6 Hz, 2H), 4.09 – 3.92 (m, 1H), 2.45 (s, 
3H), 2.06 – 1.83 (m, 4H), 1.82 – 1.57 (m, 4H), 1.52 – 1.25 (m, 8H), 0.92 (t = J = 6.3 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 159.79 (C), 158.89 (C), 143.24 (C), 135.84 (C), 135.06 
(C), 131.78 (C), 130.03 (CH), 128.67 (CH), 128.46 (C), 127.35 (CH), 123.63 (CH), 52.03 
(CH2), 47.48 (CH), 31.64 (CH2 x2), 27.78 (CH2), 27.16 (CH2), 24.60 (CH2), 23.59 (CH2 x2), 
21.30 (CH2), 19.19 (CH3), 12.93 (CH3); MS (ESI): C23H30ClN3O2 requires m/z 415.2, found 
416.2 [M + 1]+; Anal. calcd for C23H30ClN3O2: C, 66.41; H, 7.27; N, 10.10; Found: C, 66.50; 
H, 7.25; N, 10.13. 
6-(4-Chloro-3-methylphenyl)-N-cycloheptyl-3-oxo-2-pentyl-2,3-dihydropyridazine-4-
carboxamide (24): General procedure A for the synthesis of carboxamides was used to 
convert acid 44 and cycloheptylamine into the title product. The mixture of reaction was 
stirred for 18 h, then the crude of reaction was purified by flash chromatography 
(petroleum ether/EtOAc 9:1) to afford 24 (115 mg, 27%) as a colourless oil. Rf = 0.75 
(petroleum ether/EtOAc 8:2); IR 1681 (C=O), 3290 (NH); 1H NMR (400 MHz, Chloroform-
d) δ 9.75 (d, J = 8.1 Hz, 1H, NH, exch. with D2O), 8.65 (s, 1H), 7.73 (s, 1H), 7.63 (d, J = 
8.3 Hz, 1H), 7.43 (d, J = 8.3 Hz, 1H), 4.31 (t, J = 7.5 Hz, 2H), 4.22 – 4.12 (m, 1H), 2.45 (s, 
3H), 2.05 – 1.96 (m, 2H), 1.95 – 1.85 (m, 2H), 1.80 – 1.48 (m, 10H), 1.45 – 1.35 (m, 4H), 
0.93 (t, J = 6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 160.57 (C), 159.90 (C), 144.25 (C), 
136.85 (C), 136.08 (C), 132.80 (C), 131.00 (CH), 129.70 (CH), 129.50 (C), 128.37 (CH), 
124.63 (CH), 53.04 (CH2), 50.78 (CH), 34.71 (CH2 x2), 28.80 (CH2), 28.18 (CH2 x2), 28.11 
(CH2 x2), 24.10 (CH2), 22.33 (CH2), 20.21 (CH3), 13.96 (CH3).; MS (ESI): C24H32ClN3O2 
requires m/z 429.2, found 430.3 [M + 1]+; Anal. calcd for C24H32ClN3O2: C, 67.04; H, 7.50; 
N, 9.77; Found: C, 67.01; H, 7.49; N, 9.75. 
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Figure S1. 1H-NMR (CDCl3, 400 MHz): Compound 2
 
 
Figure S2. 13C-APT (CDCl3, 101 MHz): Compound 2 
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Figure S3. 1H-NMR (CDCl3, 400 MHz): Compound 3
 
 
Figure S4. 13C-APT (CDCl3, 101 MHz): Compound 3
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Figure S5. 1H-NMR (CDCl3, 400 MHz): Compound 4
 
 
Figure S6. 13C-APT (CDCl3, 101 MHz): Compound 4
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Figure S7. 1H-NMR (CDCl3, 400 MHz): Compound 5 
 
 
Figure S8. 13C-APT (CDCl3, 101 MHz): Compound 5
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Figure S9. 1H-NMR (CDCl3, 400 MHz): Compound 6 
 
 
Figure S10. 13C-APT (CDCl3, 101 MHz): Compound 6
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Figure S11. 1H-NMR (CDCl3, 400 MHz): Compound 7
 
 
Figure S12. 13C-APT (CDCl3, 101 MHz): Compound 7
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Figure S13. 1H-NMR (CDCl3, 400 MHz): Compound 8
 
 
Figure S14. 13C-APT (CDCl3, 101 MHz): Compound 8
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Figure S15. 1H-NMR (CDCl3, 400 MHz): Compound 9
 
 
Figure S16. 13C-APT (CDCl3, 101 MHz): Compound 9
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Figure S17. 1H-NMR (CDCl3, 400 MHz): Compound 10
 
 
Figure S18. 13C-APT (CDCl3, 101 MHz): Compound 10
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Figure S19. 1H-NMR (CDCl3, 400 MHz): Compound 11
 
 
Figure S20. 13C-APT (CDCl3, 101 MHz): Compound 11
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Figure S21. 1H-NMR (CDCl3, 400 MHz): Compound 12
 
 
Figure S22. 13C-APT (CDCl3, 101 MHz): Compound 12
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Figure S23. 1H-NMR (CDCl3, 400 MHz): Compound 14
 
 
Figure S24. 13C-APT (CDCl3, 101 MHz): Compound 14
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Figure S25. 1H-NMR (CDCl3, 400 MHz): Compound 15
 
 
Figure S26. 13C-APT (CDCl3, 101 MHz): Compound 15 
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Figure S27. 1H-NMR (CDCl3, 400 MHz): Compound 16
 
 
Figure S28. 13C-APT (CDCl3, 101 MHz): Compound 16
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Figure S29. 1H-NMR (CDCl3, 400 MHz): Compound 17 
 
 
Figure S30. 13C-APT (CDCl3, 101 MHz): Compound 17
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Figure S31. 1H-NMR (CDCl3, 400 MHz): Compound 18
 
 
Figure S32. 13C-APT (CDCl3, 101 MHz): Compound 18
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Figure S33. 1H-NMR (CDCl3, 400 MHz): Compound 19
 
 
Figure S34. 13C-APT (CDCl3, 101 MHz): Compound 19
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Figure S35. 1H-NMR (CDCl3, 400 MHz): Compound 20
 
 
Figure S36. 13C-APT (CDCl3, 101 MHz): Compound 20
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Figure S37. 1H-NMR (CDCl3, 400 MHz): Compound 21
 
 
Figure S38. 13C-APT (CDCl3, 101 MHz): Compound 21
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Figure S39. 1H-NMR (CDCl3, 400 MHz): Compound 22
 
 
Figure S40. 13C-APT (CDCl3, 101 MHz): Compound 22
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Figure S41. 1H-NMR (CDCl3, 400 MHz): Compound 23
 
 
Figure S42. 13C-APT (CDCl3, 101 MHz): Compound 23
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SR144528 docked at the CB2R 
Figure S43. In previous work,[1] Glide docking studies of SR144528 in our CB2 inactive 
state model suggested that this ligand spans the CB2 binding pocket and uses the EC-3 
loop residue, D275, as its primary interaction site. These results are consistent with CB2 
mutation and modeling studies (see Discussion in[1]). SR144528 also has favorable 
electrostatic and van der Waals interactions with K3.28(109) and forms a number of 
aromatic stacking interactions at CB2. The chloromethylphenyl ring forms an offset parallel 
stack with W6.48(258) and also forms a T-stack with W5.43(194). Additionally, the 
methylbenzyl ring forms a tilted-T aromatic stack with W5.43(194). SR144528 has 
favorable van der Waals interactions with F2.57(87). V3.32(113), M6.55(265), L6.54(264), 
M7.40(286), and V6.51(261) (not shown). 
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Pairwise Interaction Energies for Compound 22 at CB2R State Model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table S1. Compound 22/CB2R Complex 
Residue VdW (kcal/mol) 
Electrostatic 
(kcal/mol) 
Total Energy 
(kcal/mol) 
M6.55 -0.40 -7.43 -7.82 
K3.28 -5.61 -2.08 -7.69 
F2.57 -0.19 -7.28 -7.47 
S7.39 -3.16 -4.04 -7.20 
S6.58 0.47 -4.12 -3.65 
I3.29 -0.06 -3.23 -3.28 
L6.54 0.21 -3.06 -2.85 
V6.51 -0.09 -2.50 -2.59 
F2.61 0.03 -2.40 -2.38 
Q(276) 0.03 -2.25 -2.23 
L6.59 0.13 -2.33 -2.20 
V3.32 0.06 -2.23 -2.17 
W5.43 -0.18 -1.83 -2.01 
L7.43 0.01 -2.00 -1.99 
C7.42 0.12 -2.05 -1.93 
M7.40 -0.04 -1.57 -1.61 
P(178) -0.08 -1.25 -1.34 
W6.48 0.04 -1.26 -1.22 
S2.60 0.09 -1.17 -1.07 
A7.36 0.00 -0.83 -0.83 
F2.64 -0.03 -0.64 -0.67 
D(275) 0.04 -0.54 -0.49 
R(177) -0.03 -0.38 -0.41 
T3.33 -0.01 -0.35 -0.36 
C7.38 -0.05 -0.21 -0.26 
T(272) -0.07 -0.18 -0.25 
L4.61 -0.02 -0.23 -0.25 
A2.58 -0.01 -0.22 -0.23 
I7.44 0.03 -0.17 -0.14 
Y5.39 0.39 -0.39 0.00 
Conf Expense   0.89 
Grand Total   -65.70 
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In silico ADMET parameters 
Table S2. Metabolism parameters of compounds 2-24, SR144528 and HU308 
calculated with the admetSAR prediction tool. 
Compound CYP substrate/ inhibition
 a 
CYP3A4 CYP2C9 CYP2D6 
2 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
3 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
4 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
5 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
6 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
7 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
8 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
9 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
10 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
11 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
12 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
13 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
14 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
15 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
16 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
17 substrate/ 
inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
18 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
19 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
20 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
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21 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
22 substrate/ non-inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
23 substrate/ non-inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
24 substrate/ non-inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
HU308 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
SR144528 substrate/ inhibitor 
non-substrate/ 
non-inhibitor 
non-substrate/ 
non-inhibitor 
[a] Molecules were classified as substrate or non-substrate, and inhibitor or non-
inhibitor of the different  CYP450 isoforms according to the previously published 
classification.[2,3] 
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Table S3. Toxicity parameters of compounds 2-24, SR144528 and HU308 calculated with 
the admetSAR prediction tool. 
Compound hERG blockage [a] 
AMES 
toxicity[b] Carcinogenicity
[c] Acute oral toxicity[d] 
LD50 
in rat[d] 
2 weak inhibitor nontoxic noncarcinogenic III 2.4069 
3 weak inhibitor nontoxic noncarcinogenic III 2.4069 
4 weak inhibitor nontoxic noncarcinogenic III 2.4055 
5 weak inhibitor nontoxic noncarcinogenic III 2.4057 
6 weak inhibitor nontoxic noncarcinogenic III 2.4241 
7 weak inhibitor nontoxic noncarcinogenic III 2.3635 
8 weak inhibitor nontoxic noncarcinogenic III 2.3635 
9 weak inhibitor nontoxic noncarcinogenic III 2.3485 
10 weak inhibitor nontoxic noncarcinogenic III 2.3573 
11 weak inhibitor nontoxic noncarcinogenic III 2.4033 
12 weak inhibitor nontoxic noncarcinogenic III 2.4032 
13 weak inhibitor nontoxic noncarcinogenic III 2.4032 
14 weak inhibitor nontoxic noncarcinogenic III 2.4107 
15 weak inhibitor nontoxic noncarcinogenic III 2.4138 
16 weak inhibitor nontoxic noncarcinogenic III 2.4413 
17 weak inhibitor nontoxic noncarcinogenic III 2.4397 
18 weak inhibitor nontoxic noncarcinogenic III 2.4397 
19 weak inhibitor nontoxic noncarcinogenic III 2.3862 
20 weak inhibitor nontoxic noncarcinogenic III 2.3977 
21 weak inhibitor nontoxic noncarcinogenic III 2.4819 
22 weak inhibitor nontoxic noncarcinogenic III 2.5119 
23 weak inhibitor nontoxic noncarcinogenic III 2.5182 
24 weak inhibitor nontoxic noncarcinogenic III 2.5259 
HU308 weak inhibitor nontoxic noncarcinogenic III 2.4010 
SR144528 weak inhibitor nontoxic noncarcinogenic III 2.5354 
[a]Predicted hERG blockade: compounds are classified according to the previously published approach[4] as: 
strong inhibitors (IC50<1 mM), ‘non-blockers’ exhibiting moderate (1– 10 mM) and weak (IC50>10 mM) 
inhibitors. [b] AMES mutagenicity predictions are based on the previously published benchmark data set.[5,6] 
[c] Carcinogenic potency is divided into three classes, labeled as "Danger", "Warning" and "Non-required", 
according to the TD50 (median toxic dose) values. Carcinogenic compounds with TD50 ≤ 10 mg/kg body 
wt/day were assigned as "Danger", those with TD50 > 10 mg/kg body wt/day were assigned as "Warning", and 
non-carcinogenic chemicals were assigned as "Non-required".[7,8] [d] Compounds are classified into four 
categories based on the criterion of US EPA (Category I contains compounds with LD50 values less than or 
equal to 50 mg/kg. Category II contains compounds with LD50 values greater than 50 mg/kg but less than 500 
mg/kg. Category III includes compounds with LD50 values greater than 500 mg/kg but less than 5000 mg/kg. 
Category IV consisted of compounds with LD50 values greater than 5000 mg/kg).[9] [e] Predicted median lethal 
dose (LD50) in rat model (Acute Toxicity in mol/kg).[10]  
S38	  
	  
References: 
[1] E. Kotsikorou, F. Navas, 3rd, M. J. Roche, A. F. Gilliam, B. F. Thomas, H. H. Seltzman, P. Kumar, Z. H. Song, D. P. Hurst, D. L. Lynch, P. H. 
Reggio, J. Med. Chem. 2013, 56, 6593-6612. 
[2] F. Cheng, Y. Yu, J. Shen, L. Yang, W. Li, G. Liu, P. W. Lee, Y. Tang, J. Chem. Inf. Mod. 2011, 51, 996-1011. 
[3] M. Carbon-Mangels, M. C. Hutter, Mol. Inform. 2011, 30, 885-895. 
[4] R. L. Marchese Robinson, R. C. Glen, J. B. O. Mitchell, Mol. Inform. 2011, 30, 443-458. 
[5] C. Xu, F. Cheng, L. Chen, Z. Du, W. Li, G. Liu, P. W. Lee, Y. Tang, J. Chem. Inf. Mod. 2012, 52, 2840-2847. 
[6] K. Hansen, S. Mika, T. Schroeter, A. Sutter, A. T. Laak, S. H. Thomas, N. Heinrich, K. R. Müller, J. Chem. Inf. Mod. 2009, 49, 2077-2081. 
[7] X. Li, Z. Du, J. Wang, Z. Wu, W. Li, G. Liu, X. Shen, Y. Tang, Mol. Inform. 2015, 34, 228-235. 
[8] A. Lagunin, D. Filimonov, A. Zakharov, W. Xie, Y. Huang, F. Zhu, T. Shen, J. Yao, V. Poroikov, QSAR Comb. Sci. 2009, 28, 806-810. 
[9] X. Li, L. Chen, F. Cheng, Z. Wu, H. Bian, C. Xu, W. Li, G. Liu, X. Shen, Y. Tang, J. Chem. Inf. Mod. 2014, 54, 1061-1069. 
[10] H. Zhu, T. M. Martin, L. Ye, A. Sedykh, D. M. Young, A. Tropsha, Chem. Res. Toxicol. 2009, 22, 1913-1921. 
